<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="49339"><DrugName>trebananib</DrugName><DrugNamesKey><Name id="42959262">trebananib</Name></DrugNamesKey><DrugSynonyms><Name><Value>tie-2 tyrosine kinase receptor antagonists (cancer), Amgen/Takeda</Value></Name><Name><Value>tie-2 tyrosine kinase receptor antagonists, Amgen/Takeda</Value></Name><Name><Value>tie-2 receptor antagonists, Amgen/Takeda</Value></Name><Name><Value>AMG-386</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Peptidobody tie-2 tyrosine kinase receptor antagonists, Amgen</Value></Name><Name><Value>2xCon4C</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Ab536</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>Angiopoietin-2 antagonists (cancer), Amgen/Takeda</Value></Name><Name><Value>Ang-2 antagonists (cancer), Amgen/Takeda</Value></Name><Name><Value>trebananib</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name><Name><Value>L1-7</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="14109">Amgen Inc</CompanyOriginator><CompaniesSecondary><Company id="14109">Amgen Inc</Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Company id="23215">Takeda Bio Development Center Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="49339" type="Drug"><TargetEntity id="384887" type="siDrug">Trebananib</TargetEntity></SourceEntity><SourceEntity id="14109" type="Company"><TargetEntity id="4295905537" type="organizationId">Amgen Inc</TargetEntity></SourceEntity><SourceEntity id="20300" type="Company"><TargetEntity id="4295877353" type="organizationId">Takeda Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="23215" type="Company"><TargetEntity id="5000057942" type="organizationId">Takeda Bio Development Center Ltd</TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"/><TargetEntity id="D002289" type="MeSH"/><TargetEntity id="-1730468577" type="omicsDisease"/><TargetEntity id="612" type="siCondition"/></SourceEntity><SourceEntity id="131" type="ciIndication"><TargetEntity id="C26" type="ICD10"/><TargetEntity id="159" type="ICD9"/><TargetEntity id="10061174" type="MEDDRA"/><TargetEntity id="D005770" type="MeSH"/><TargetEntity id="-1015825676" type="omicsDisease"/><TargetEntity id="602" type="siCondition"/></SourceEntity><SourceEntity id="1767" type="ciIndication"><TargetEntity id="D006528" type="MeSH"/><TargetEntity id="88673" type="ORPHANET"/><TargetEntity id="-1116061312" type="omicsDisease"/><TargetEntity id="1973" type="siCondition"/></SourceEntity><SourceEntity id="1771" type="ciIndication"><TargetEntity id="10044412" type="MEDDRA"/><TargetEntity id="D002295" type="MeSH"/><TargetEntity id="-807613677" type="omicsDisease"/><TargetEntity id="677" type="siCondition"/></SourceEntity><SourceEntity id="2243" type="ciIndication"><TargetEntity id="C57.0" type="ICD10"/><TargetEntity id="10016180" type="MEDDRA"/><TargetEntity id="D005185" type="MeSH"/><TargetEntity id="-33569282" type="omicsDisease"/><TargetEntity id="600" type="siCondition"/></SourceEntity><SourceEntity id="2454" type="ciIndication"><TargetEntity id="10018336" type="MEDDRA"/><TargetEntity id="D005909" type="MeSH"/><TargetEntity id="360" type="ORPHANET"/><TargetEntity id="-1357419475" type="omicsDisease"/><TargetEntity id="678" type="siCondition"/></SourceEntity><SourceEntity id="3083" type="ciIndication"><TargetEntity id="C48" type="ICD10"/><TargetEntity id="10061344" type="MEDDRA"/><TargetEntity id="D010534" type="MeSH"/><TargetEntity id="-745704479" type="omicsDisease"/><TargetEntity id="633" type="siCondition"/></SourceEntity><SourceEntity id="3460" type="ciIndication"><TargetEntity id="10053548" type="MEDDRA"/></SourceEntity><SourceEntity id="3467" type="ciIndication"><TargetEntity id="1233" type="siCondition"/></SourceEntity><SourceEntity id="3665" type="ciIndication"><TargetEntity id="10059515" type="MEDDRA"/><TargetEntity id="613" type="siCondition"/></SourceEntity><SourceEntity id="3667" type="ciIndication"><TargetEntity id="10055102" type="MEDDRA"/></SourceEntity><SourceEntity id="3866" type="ciIndication"><TargetEntity id="10057529" type="MEDDRA"/><TargetEntity id="629" type="siCondition"/></SourceEntity><SourceEntity id="49" type="ciIndication"><TargetEntity id="C50" type="ICD10"/><TargetEntity id="10006279" type="MEDDRA"/><TargetEntity id="D001943" type="MeSH"/><TargetEntity id="-436099203" type="omicsDisease"/><TargetEntity id="588" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"/></SourceEntity><SourceEntity id="799" type="ciIndication"><TargetEntity id="C56" type="ICD10"/><TargetEntity id="10033128" type="MEDDRA"/><TargetEntity id="D010051" type="MeSH"/><TargetEntity id="-1370909262" type="omicsDisease"/><TargetEntity id="626" type="siCondition"/></SourceEntity><SourceEntity id="989" type="ciIndication"><TargetEntity id="10061451" type="MEDDRA"/><TargetEntity id="D015179" type="MeSH"/><TargetEntity id="-1280257855" type="omicsDisease"/><TargetEntity id="594" type="siCondition"/></SourceEntity><SourceEntity id="14320" type="Action"><TargetEntity id="3895" type="Mechanism">Anti-ANGPT1 (Angiopoietin 1)</TargetEntity></SourceEntity><SourceEntity id="3834" type="Action"><TargetEntity id="2853" type="Mechanism">Anti-Tie2</TargetEntity><TargetEntity id="1154" type="Mechanism">Tie2 Receptor Inhibitors</TargetEntity></SourceEntity><SourceEntity id="14323" type="Action"><TargetEntity id="3168" type="Mechanism">Anti-ANGPT2 (Angiopoietin 2)</TargetEntity></SourceEntity><SourceEntity id="61" type="Action"><TargetEntity id="885" type="Mechanism">Angiogenesis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-01826" type="ciTarget"><TargetEntity id="120477287970103" type="siTarget">Angiopoietin-1 receptor</TargetEntity><TargetEntity id="782" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-03653" type="ciTarget"><TargetEntity id="1346610742843" type="siTarget">Angiopoietin-1</TargetEntity><TargetEntity id="8162" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-03654" type="ciTarget"><TargetEntity id="16397075482853" type="siTarget">Angiopoietin-2</TargetEntity><TargetEntity id="8067" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C3">Phase 3 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="1262">Non-small-cell lung cancer</Indication><Indication id="131">Gastrointestinal tumor</Indication><Indication id="1767">Hepatocellular carcinoma</Indication><Indication id="1771">Transitional cell carcinoma</Indication><Indication id="2243">Fallopian tube cancer</Indication><Indication id="2454">Glioblastoma</Indication><Indication id="3083">Peritoneal tumor</Indication><Indication id="3460">Metastatic gastrointestinal cancer</Indication><Indication id="3467">Metastatic renal cancer</Indication><Indication id="3665">Metastatic non small cell lung cancer</Indication><Indication id="3667">Metastatic esophageal cancer</Indication><Indication id="3866">Metastatic ovary cancer</Indication><Indication id="49">Breast tumor</Indication><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication><Indication id="799">Ovary tumor</Indication><Indication id="989">Colorectal tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="3834">Tek tyrosine kinase receptor inhibitor</Action><Action id="14323">Angiopoietin ligand-2 inhibitor</Action><Action id="14320">Angiopoietin ligand-1 inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="62255">Anticancer protein kinase inhibitor</Action><Action id="61">Angiogenesis inhibitor</Action></ActionsSecondary><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="80">Peptide</Technology><Technology id="84">Protein fusion</Technology><Technology id="180">Antibody fragment</Technology><Technology id="648">Intravenous formulation</Technology></Technologies><LastModificationDate>2018-05-16T07:52:51.000Z</LastModificationDate><ChangeDateLast>2017-11-20T00:00:00.000Z</ChangeDateLast><AddedDate>2004-03-25T13:17:50.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="14109" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="23215" linkType="Company"&gt;&lt;/ulink&gt;&lt;ulink linkID="20300" linkType="Company"&gt;Takeda Pharmaceutical&lt;/ulink&gt; was developing trebananib (AMG-386), the lead  in a series of peptibodies (an Fc fragment linked to peptides) that inhibits the interaction between Tie-2 (TEK) and its ligands Ang1  (angiopoietin1) and  Ang2 (angiopoietin2), for the potential treatment of  cancer [&lt;ulink linkID="528612" linkType="reference"&gt;528612&lt;/ulink&gt;], [&lt;ulink linkID="528690" linkType="reference"&gt;528690&lt;/ulink&gt;], [&lt;ulink linkID="528696" linkType="reference"&gt;528696&lt;/ulink&gt;], [&lt;ulink linkID="879806" linkType="Reference"&gt;879806&lt;/ulink&gt;], [&lt;ulink linkID="892192" linkType="Reference"&gt;892192&lt;/ulink&gt;], [&lt;ulink linkID="1173756" linkType="Reference"&gt;1173756&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;By March 2010, a phase III program for ovarian cancer  had commenced [&lt;ulink linkID="1096272" linkType="Reference"&gt;1096272&lt;/ulink&gt;]. A phase III trial in first-line advanced ovarian cancer (in combination with &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; and carboplatin) began in 2011 [&lt;ulink linkID="1267859" linkType="Reference"&gt;1267859&lt;/ulink&gt;]. By March 2010, a phase III program for recurrent ovarian cancer had also begun [&lt;ulink linkID="1096272" linkType="Reference"&gt;1096272&lt;/ulink&gt;],  [&lt;ulink linkID="1137669" linkType="Reference"&gt;1137669&lt;/ulink&gt;]; positive topline data were reported in June 2013 [&lt;ulink linkID="1437876" linkType="Reference"&gt;1437876&lt;/ulink&gt;]. However, in December 2014, it was reported that clinical development in recurrent ovarian cancer had been terminated, with phase III development to continue only in  first-line advanced ovarian cancer  [&lt;ulink linkID="1645758" linkType="Reference"&gt;1645758&lt;/ulink&gt;]. In April 2015, the phase III first-line advanced ovarian cancer trial was also terminated on a recommendation by the Data Safety Monitoring Board [&lt;ulink linkID="1688729" linkType="Reference"&gt;1688729&lt;/ulink&gt;], [&lt;ulink linkID="1736448" linkType="Reference"&gt;1736448&lt;/ulink&gt;]. By February 2016, development in first-line ovarian cancer had been discontinued [&lt;ulink linkID="1736448" linkType="Reference"&gt;1736448&lt;/ulink&gt;]. In February 2016, the drug was still listed as being in phase III development for ovarian cancer in Japan by Takeda [&lt;ulink linkID="1732358" linkType="Reference"&gt;1732358&lt;/ulink&gt;]; however, in June 2016, Takeda returned all rights to the drug to Amgen [&lt;ulink linkID="1775723" linkType="Reference"&gt;1775723&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Amgen was previously codeveloping the drug for several cancer indications, including ovarian cancer; however, in February 2016, development of the drug was discontinued [&lt;ulink linkID="1776078" linkType="Reference"&gt;1776078&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Amgen was developing the drug for other cancer indications.  By September 2007, phase II trials for renal cell carcinoma and for first-line HER2-negative breast cancer had begun [&lt;ulink linkID="824548" linkType="Reference"&gt;824548&lt;/ulink&gt;],  [&lt;ulink linkID="832324" linkType="Reference"&gt;832324&lt;/ulink&gt;]. In December 2007, a phase II metastatic gastric cancer trial commenced; in June 2012, the trial was completed [&lt;ulink linkID="882094" linkType="Reference"&gt;882094&lt;/ulink&gt;]. In November 2008, a phase II trial in colorectal cancer began; in June 2012, the trial was completed [&lt;ulink linkID="1086208" linkType="Reference"&gt;1086208&lt;/ulink&gt;]. A phase I/II trial in metastatic non-squamous non-small-cell lung cancer (NSCLC) was initiated in August 2012 [&lt;ulink linkID="1341524" linkType="Reference"&gt;1341524&lt;/ulink&gt;]; however, in  October 2013, Amgen announced it was discontinuing enrollment in the trial as the therapeutic landscape in NSCLC was said to limit the potential utility of trebananib in the study [&lt;ulink linkID="1493434" linkType="Reference"&gt;1493434&lt;/ulink&gt;]. In August 2009, a phase II trial in hepatocellular cancer  was initiated; in July 2015, the trial was completed [&lt;ulink linkID="1220037" linkType="Reference"&gt;1220037&lt;/ulink&gt;].   In January 2011, a phase II glioblastoma trial was initiated [&lt;ulink linkID="1178458" linkType="Reference"&gt;1178458&lt;/ulink&gt;]. In July 2013, a phase II study in advanced transitional cell carcinoma of urothelial origin was expected to start in December 2013; however, by April 2014, the trial was withdrawn after the sponsor decided to terminate the study [&lt;ulink linkID="1468356" linkType="Reference"&gt;1468356&lt;/ulink&gt;]. No development for transitional cell carcinoma has been reported since.&lt;/para&gt;&lt;para&gt;Amgen was previously investigating the fully human  antibody,  Ab536,  and  peptibodies, 2xCon4C and L1-7, for the potential treatment of cancer. By November 2005, these were in preclinical development [&lt;ulink linkID="634908" linkType="Reference"&gt;634908&lt;/ulink&gt;]. However, in February 2011, they  were not  listed on the Amgen pipeline and development was presumed to have been  discontinued  [&lt;ulink linkID="1173756" linkType="Reference"&gt;1173756&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In October 2002, development of a polypeptide capable of binding to Ang-2, was claimed under &lt;ulink linkID="PA2865025" linkType="Patent"&gt;WO-03057134&lt;/ulink&gt;. In March 2012, Amgen noted that it had patent protection in the US to 2025, and coverage in Europe expiring 2019 to 2022 [&lt;ulink linkID="1267859" linkType="Reference"&gt;1267859&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In August 2013, the FDA granted trebananib Orphan designation for the treatment of ovarian cancer [&lt;ulink linkID="1476453" linkType="Reference"&gt;1476453&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In October 2013, the EMA's COMP recommended granting trebananib Orphan status for the treatment of ovarian cancer [&lt;ulink linkID="1488978" linkType="Reference"&gt;1488978&lt;/ulink&gt;]; in November 2013, Orphan status was granted [&lt;ulink linkID="1515390" linkType="Reference"&gt;1515390&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Ovarian, primary peritoneal and fallopian tube cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In September 2011, a randomized, placebo-controlled, double-blind, phase III study (&lt;ulink linkID="83324" linkType="Protocol"&gt;NCT01493505&lt;/ulink&gt;; TRINOVA-3) began to evaluate trebananib in the first-line treatment of patients with stage 3 or 4 ovarian cancer. Patients would receive trebananib (15 mg/kg weekly) plus paclitaxel and carboplatin, or placebo plus paclitaxel and carboplatin; the primary endpoint was progression-free survival (PFS) over 3 years, with overall survival over 5 years the secondary endpoint. The trial was expected to enroll 2000 patients and complete in July 2020 [&lt;ulink linkID="1296216" linkType="Reference"&gt;1296216&lt;/ulink&gt;]. In November 2014, data were expected in 2015 [&lt;ulink linkID="1608372" linkType="Reference"&gt;1608372&lt;/ulink&gt;]. In April 2015, however, the company terminated dosing in the trial based on a recommendation by the Data Safety Monitoring Committee, suggesting that the primary PFS endpoint was unlikely to be met [&lt;ulink linkID="1688729" linkType="Reference"&gt;1688729&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, a multinational, randomized, double-blind, parallel-assignment, phase III trial (&lt;ulink linkID="73978" linkType="Protocol"&gt;NCT01281254&lt;/ulink&gt;; 20060517; EudraCT Number 2009-017946-30; ENGOT-ov-6; TRINOVA-2) began recruitment (expected n = 380) in the US, Europe, Australia, New Zealand and the Far East with recurrent partially platinum-sensitive or -resistant epithelial ovarian, primary peritoneal or fallopian tube cancer. Patients were to be treated with monthly Doxil plus trebananib (15 mg/kg weekly) or placebo. The primary endpoint was PFS. At that time, the trial was estimated to complete in June 2018 [&lt;ulink linkID="1220001" linkType="Reference"&gt;1220001&lt;/ulink&gt;]. In October 2011,  Amgen disclosed a potential delay in  enrollment due to shortages of Doxil, although that was not expected to delay registration using data from the TRINOVA-1 study [&lt;ulink linkID="1236164" linkType="Reference"&gt;1236164&lt;/ulink&gt;], [&lt;ulink linkID="1251779" linkType="Reference"&gt;1251779&lt;/ulink&gt;]. By January 2012, the TRINOVA-2 trial had been suspended due to the Doxil shortages [&lt;ulink linkID="1257983" linkType="Reference"&gt;1257983&lt;/ulink&gt;]. By January 2013, the trial had resumed [&lt;ulink linkID="1362443" linkType="Reference"&gt;1362443&lt;/ulink&gt;]. In October 2013, Amgen announced it had discontinued enrollment due to the Doxil supply issues [&lt;ulink linkID="1493434" linkType="Reference"&gt;1493434&lt;/ulink&gt;].  In October 2014, PFS data were expected in 2015 [&lt;ulink linkID="1606039" linkType="Reference"&gt;1606039&lt;/ulink&gt;]. In November 2014, however, it was announced that the trial had failed to meet its primary endpoint [&lt;ulink linkID="1645758" linkType="Reference"&gt;1645758&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2010, a phase III program for ovarian cancer  had commenced [&lt;ulink linkID="1096272" linkType="Reference"&gt;1096272&lt;/ulink&gt;]. In October 2010, a multinational, randomized (1:1), double-blind, parallel-assignment, phase III trial (&lt;ulink linkID="70434" linkType="Protocol"&gt;NCT01204749&lt;/ulink&gt;; 20090508; TRINOVA-1) was initiated in women (expected n = 900) with recurrent partially platinum-sensitive or -resistant epithelial ovarian, primary peritoneal or fallopian tube cancer. Patients were to be treated with &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; plus trebananib (15 mg/kg weekly), or placebo plus paclitaxel. The primary endpoint was progression-free survival (PFS). At that time, the trial was estimated to complete in April 2017. In December 2010, patient recruitment began in the US, Europe, Canada, Australia, the Far East, Chile, Mexico, Israel and South Africa [&lt;ulink linkID="1137669" linkType="Reference"&gt;1137669&lt;/ulink&gt;], [&lt;ulink linkID="1219736" linkType="Reference"&gt;1219736&lt;/ulink&gt;]. In January 2011, Takeda Bio initiated the study at Japanese sites [&lt;ulink linkID="1162980" linkType="Reference"&gt;1162980&lt;/ulink&gt;]. In May 2012, recruitment was ongoing [&lt;ulink linkID="1219736" linkType="Reference"&gt;1219736&lt;/ulink&gt;]. In June 2013, top-line data were reported. The trial met its primary endpoint, with a significant improvement in PFS observed in the trebananib group; median PFS was 7.2 and 5.4 months for the trebananib and control arms, respectively. A trend towards improved overall survival was also observed; at that time, mature overall survival data were expected in 2014. The most frequently reported adverse events in the trebananib group were localized edema, nausea and alopecia [&lt;ulink linkID="1437876" linkType="Reference"&gt;1437876&lt;/ulink&gt;]. In October 2013, further data were presented at the 2013 European Cancer Congress in Amsterdam, the Netherlands. The complete response and partial responses were observed in 20 and 109 patients, respectively, in the paclitaxel + placebo group and 17 and 150 patients, respectively, in the paclitaxel + trebananib group. In the paclitaxel + placebo and paclitaxel + trebananib groups, the median overall survival rates (interim analysis) were 17.3 and 19.0 months, respectively [&lt;ulink linkID="1480374" linkType="Reference"&gt;1480374&lt;/ulink&gt;]. In November 2014, overall survival secondary endpoint results were disclosed. The trial did not show significant improvement in overall survival; median overall survival was 19.3 and 18.3 months in the trebananib and control arms, respectively [&lt;ulink linkID="1608372" linkType="Reference"&gt;1608372&lt;/ulink&gt;]. In June 2015, further clinical data were presented at the 51st ASCO meeting in Chicago, IL.  After on-study progression, 74% of patients received a median of 2 additional lines of therapy and the median PFS2 in the trebananib + paclitaxel arm increased by 1.6 months (12.5 months compared to 10.9 months with paclitaxel alone)  [&lt;ulink linkID="1662674" linkType="Reference"&gt;1662674&lt;/ulink&gt;].									In November 2014, it was announced that trebananib plus paclitaxel did not significantly increase overall survival compared with paclitaxel alone, and the trial was terminated [&lt;ulink linkID="1645758" linkType="Reference"&gt;1645758&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In May 2007, a randomized, double-blind, placebo-controlled phase II trial (&lt;ulink linkID="38361" linkType="Protocol"&gt;NCT00479817&lt;/ulink&gt;; 20060342) was planned in patients (expected n = 150) with advanced (Stage II to IV) ovarian cancer or primary peritoneal cancer. The study was to test the drug (3 or 10 mg/kg2) in combination with paclitaxel, compared to paclitaxel and placebo  [&lt;ulink linkID="801916" linkType="Reference"&gt;801916&lt;/ulink&gt;]. By September 2007, the trial had begun  in the US, Belgium, Canada, Australia and India  [&lt;ulink linkID="809143" linkType="Reference"&gt;809143&lt;/ulink&gt;]. Data were presented at the 46th ASCO meeting in June 2010. PFS, the primary endpoint, significantly increased from 4.6 months with placebo to 7.2 months in the high-dose AMG 386 arm [&lt;ulink linkID="1105066" linkType="Reference"&gt;1105066&lt;/ulink&gt;]. Further data were presented in October 2010 at the 35th European Society for Medical Oncology Congress in Milan, Italy. Overall survival in the 10 mg/kg trebananib cohort was 22.5 months compared with 20.4 months in the 3 mg/kg arm and 20.9 months in the placebo group. Median progression-free survival was 7.3, 7.4  and 5 months, while the objective response rate was 37, 21 and 27%, respectively [&lt;ulink linkID="1137669" linkType="Reference"&gt;1137669&lt;/ulink&gt;]. In June 2012,  a crossover study was presented at the 48th ASCO meeting in Chicago, IL. Post-hoc analyses from&lt;b&gt; &lt;/b&gt;161 randomized patients showed that in 18 patients given open-label trebananib monotherapy, progression-free survival was 3.2 months. Patients given monotherapy, who had high exposure AMG-386 also had longer progression-free survival  than those with low exposure [&lt;ulink linkID="1296773" linkType="Reference"&gt;1296773&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In January 2011, a non-randomized, single-group assignment, open-label, phase I trial (&lt;ulink linkID="72840" linkType="Protocol"&gt;NCT01253681&lt;/ulink&gt;; 20090155) evaluating trebananib in combination with &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; and &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; began in patients (expected n = 25) in Australia, Belgium and Spain with high-risk Stage I or Stages II to IV epithelial ovarian, primary peritoneal or fallopian tube cancers. The primary endpoint was safety and tolerability of the combination. At that time, the trial was expected to complete in November 2013 [&lt;ulink linkID="1220435" linkType="Reference"&gt;1220435&lt;/ulink&gt;]. In June 2012, data were presented at the 48th ASCO meeting in Chicago, IL. The regimen, with trebananib at 15 mg/kg qw, was well tolerated. One serious Grade 3 adverse event of decreased appetite requiring hospitalization was seen, and one  patient discontinued, due to disease progression and death. At the time of analysis 15 patients remained on the study [&lt;ulink linkID="1296762" linkType="Reference"&gt;1296762&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, a phase I, non-randomized, open-label,   parallel-assignment study (&lt;ulink linkID="35967" linkType="Protocol"&gt;NCT00770536&lt;/ulink&gt;) of the agent in combination with  &lt;ulink linkID="7934" linkType="Drug"&gt;liposomal doxorubicin&lt;/ulink&gt; or &lt;ulink linkID="4577" linkType="Drug"&gt;topotecan&lt;/ulink&gt; began in the US, Australia and Belgium in patients (estimated n = 100)  with recurrent ovarian cancer. The primary endpoint was the incidence of adverse events and clinical laboratory abnormalities defined as DLT. At that time, the trial was estimated to complete in November 2011. In January 2011, recruitment was ongoing [&lt;ulink linkID="961451" linkType="Reference"&gt;961451&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Glioblastoma&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In January 2011, a non-randomized, open-label, phase II study (&lt;ulink linkID="74482" linkType="Protocol"&gt;NCT01290263&lt;/ulink&gt;; 00021773) was initiated in patients with recurrent glioblastoma multiforme (expected n = 68) in the US, to assess the safety and efficacy of trebananib. At that time, the study was expected to complete in December 2016.  In October 2015, the trial was ongoing [&lt;ulink linkID="1178458" linkType="Reference"&gt;1178458&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Hepatocellular cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In August 2009, a non-randomized, open-label, parallel-assignment, safety and efficacy, phase II trial (&lt;ulink linkID="50186" linkType="Protocol"&gt;NCT00872014&lt;/ulink&gt;; 20080580) began in patients (expected n = 60) in the US, Australia, France and Germany with advanced or inoperable hepatocellular cancer who had not received any prior systemic therapy except surgery or locoregional therapy. The primary endpoint was progression-free survival rate at 4 months. At that time, the trial was estimated to complete in May 2015. In July 2011, the trial was recruiting participants. In June 2013, the trial was ongoing but no longer recruiting patients; at that time, the trial was expected to complete in June 2015   [&lt;ulink linkID="1220037" linkType="Reference"&gt;1220037&lt;/ulink&gt;]. In January 2014, clinical data were presented at the 2014 Gastrointestinal Cancers Symposium in San Francisco, CA. A progression-free survival was observed in 57 and 54% of patients receiving the 10- and 15-mg/kg doses, respectively. The respective overall survival values were 17 and 11 months and the respective median time to progression was 9 and 7 months. Compared with historical controls, the study did not show any improvement in progression-free survival at 4 months [&lt;ulink linkID="1517527" linkType="Reference"&gt;1517527&lt;/ulink&gt;]. In July 2015, the trial was completed [&lt;ulink linkID="1220037" linkType="Reference"&gt;1220037&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In November 2008, a phase II study (&lt;ulink linkID="39258" linkType="Protocol"&gt;NCT00752570&lt;/ulink&gt;) was initiated in the US in patients with previously treated metastatic colorectal cancer. The trial, which was to compare trebananib + FOLFIRI to FOLFIRI alone, was expected to enroll 138 patients and  complete in February 2013 [&lt;ulink linkID="1086208" linkType="Reference"&gt;1086208&lt;/ulink&gt;]. Data were presented at the World Congress on Gastrointestinal Cancer in June 2011. In the 145 patients enrolled, PFS was not improved with the addition of trebananib to FOLFIRI (5.2 vs 3.5 months). However, in the assessable population, overall survival rates were 14% in the trebananib + FOLFIRI group vs 0% for FOLFIRI alone [&lt;ulink linkID="1304487" linkType="Reference"&gt;1304487&lt;/ulink&gt;]. In June 2012, the trial was completed [&lt;ulink linkID="1086208" linkType="Reference"&gt;1086208&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Gastric cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In December 2007, a  randomized, double-blind, phase II trial (&lt;ulink linkID="38300" linkType="Protocol"&gt;NCT00583674&lt;/ulink&gt;, 20060439) was initiated in patients (expected n = 165) with metastatic gastric, gastroesophageal junction or distal esophageal adenocarcinoma in Australia, Belgium and France. The patients were to receive trebananib (3 or 10 mg/kg iv once weekly) in combination with cisplatin (80 mg/m2 iv thrice weekly) and &lt;ulink linkID="12205" linkType="Drug"&gt;capecitabine&lt;/ulink&gt; (1000 mg/m2 po bid), compared to cisplatin and capecitabine alone. The primary endpoint was progression-free survival. At that time, the trial was expected to complete in July 2013 [&lt;ulink linkID="882094" linkType="Reference"&gt;882094&lt;/ulink&gt;]. By January 2011, the trial was ongoing, but was  no longer recruiting participants. A total of 171 patients had been recruited [&lt;ulink linkID="882094" linkType="Reference"&gt;882094&lt;/ulink&gt;]. Data were presented at ASCO in June 2011. In the 171 patients, PFS was 4.2 and 4.9 months in the trenananib 3 mg/kg and 10 mg/kg groups, respectively, compared to 5.2 months for cisplatin and capecitabine alone. Overall response rate in the three groups was 27, 43 and 35%, respectively [&lt;ulink linkID="1304474" linkType="Reference"&gt;1304474&lt;/ulink&gt;]. In June 2012, the trial was completed [&lt;ulink linkID="882094" linkType="Reference"&gt;882094&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Breast cancer&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In March 2010, a randomized, open-label, parallel-assignment, phase II trial (&lt;ulink linkID="63141" linkType="Protocol"&gt;NCT01042379&lt;/ulink&gt;; 097517; Investigation of serial studies to predict your therapeutic response with imaging and molecular analysis 2 (I-SPY 2)) was initiated by a precompetitive consortium in the US  in patients (expected n = 800) with breast cancer. The primary endpoint was to determine whether adding experimental agents to standard neoadjuvant medications increased the probability of pathologic complete response over standard neoadjuvant chemotherapy for each biomarker signature established at trial entry. The trial was to assess trebananib monotherapy or in combination with &lt;ulink linkID="6386" linkType="Drug"&gt;trastuzumab&lt;/ulink&gt;. At that time, the trial was expected to complete in November 2014. In December 2015, the trial was ongoing and expected to complete in September 2017 [&lt;ulink linkID="1509108" linkType="Reference"&gt;1509108&lt;/ulink&gt;], [&lt;ulink linkID="1533951" linkType="Reference"&gt;1533951&lt;/ulink&gt;]. In December 2015, further clinical data were presented at the 38th Annual San Antonio Breast Cancer Symposium in San Antonio, TX. Activity was observed in hormone receptor-negative (HR-), MammaPrint  high 2 (MP2), HR-/ human EGFR-2 (HER2)- and HR-/HER2+ tumors. There was only minor toxicity including neutropenia (11%) and anemia (8%) was reported. Overall, trebananib was well-tolerated and showed benefit in HR-, MP2 (highly correlated with HR-), HR-/HER2- and HR-/HER2+ tumors [&lt;ulink linkID="1721770" linkType="Reference"&gt;1721770&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2007, a placebo-controlled, randomized, double-blind, phase II trial (&lt;ulink linkID="38301" linkType="Protocol"&gt;NCT00511459&lt;/ulink&gt;, 20060341) was initiated in the US, Europe, Australia and India in previously untreated patients (expected n = 220) with HER2-negative locally recurrent and metastatic breast cancer. Patients would receive trebananib in combination with &lt;ulink linkID="8047" linkType="Drug"&gt;bevacizumab&lt;/ulink&gt; and &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt;, or paclitaxel. The primary endpoint was progression-free survival. The study was still recruiting in September 2007 [&lt;ulink linkID="824548" linkType="Reference"&gt;824548&lt;/ulink&gt;]. In June 2011, data from the multicenter, safety, pharmacokinetic and efficacy trial were presented at the 47th ASCO meeting in Chicago, IL. Patients received iv qw trebananib (10 mg/kg (n = 56; group 1) or 3 mg/kg (n = 57; group 2), or placebo, qw, plus paclitaxel and bevacizumab (n = 58; group 3) or open-label trebananib (10 mg/kg qw) plus paclitaxel (n = 57; group 4). The median  PFS in groups 1, 2, 3 and 4 was 11.3, 9.2, 12.2 and 10 months. The exposure of bevacizumab at steady state appeared to be similar when given in combination with placebo and trebananib [&lt;ulink linkID="1194092" linkType="Reference"&gt;1194092&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In March 2009, a non-randomized, parallel-assignment, open-label, phase I trial (&lt;ulink linkID="38484" linkType="Protocol"&gt;NCT00807859&lt;/ulink&gt;; 20062042) evaluating trebananib in combination with either &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; and &lt;ulink linkID="6386" linkType="Drug"&gt;trastuzumab&lt;/ulink&gt; (cohort A) or &lt;ulink linkID="12205" linkType="Drug"&gt;capecitabine&lt;/ulink&gt; and &lt;ulink linkID="33591" linkType="Drug"&gt;lapatinib&lt;/ulink&gt; (cohort B) began in patients (expected n = 58) in the US, Belgium and France with HER2-positive locally recurrent or metastatic breast cancer. The primary endpoint was the incidence of adverse events and clinical laboratory abnormalities defined as a DLT. At that time, the trial was estimated to complete in October 2012. In September 2011, the trial was recruiting participants [&lt;ulink linkID="1220430" linkType="Reference"&gt;1220430&lt;/ulink&gt;]. In June 2012, data were presented at the 48th ASCO meeting in Chicago, IL.  In cohort A1 (trebananib at 10 mg/kg), one patient had a DLT, with a grade 3 transient ischemic attack. No DLTs were seen in cohorts A3 (trebananib at 30 mg/kg) or B1 (trebananib at 10 mg/kg). Edema occurred in both treatment cohorts but was considered manageable [&lt;ulink linkID="1299497" linkType="Reference"&gt;1299497&lt;/ulink&gt;]. In July 2013, the trial was expected to complete in July 2014 [&lt;ulink linkID="1220430" linkType="Reference"&gt;1220430&lt;/ulink&gt;]. In May 2014, further data were presented at the 50th ASCO meeting in Chicago, IL. Of the 37 patients evaluable for response, 3 patients had complete response and 28 patients had partial response. The confirmed objective response rates at 10 and 30 mg/kg dose levels were 80 and 88.2%, respectively.  In the 10 and 30 mg dose groups, the median progression-free survival was 14.5 and 18.7 months, respectively [&lt;ulink linkID="1563357" linkType="Reference"&gt;1563357&lt;/ulink&gt;]. In December 2014, further data were presented at the 37th Annual San Antonio Breast Cancer Symposium, San Antonio, TX. The median progression free survival was 14.5, 18.5 and 8.6 months in the cohort A1, A3 and B1, respectively. The confirmed objective response (complete response or partial response) was 80, 88.2 and 50% in the cohort A1, A3 and B1, respectively [&lt;ulink linkID="1616569" linkType="Reference"&gt;1616569&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Renal cell carcinoma&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2009, a non-randomized, parallel-assignment, open-label, safety and efficacy phase II trial (&lt;ulink linkID="47602" linkType="Protocol"&gt;NCT00853372&lt;/ulink&gt;; 20080579) evaluating the drug in combination with &lt;ulink linkID="12973" linkType="Drug"&gt;sunitinib&lt;/ulink&gt; as first-line or second-line therapy began in patients (expected n = 85) in the US with metastatic RCC. The primary endpoint was safety and tolerability of the combination treatment. At that time, the trial was estimated to complete in May 2015. In February 2011, the trial was ongoing, but was no longer recruiting participants [&lt;ulink linkID="1220407" linkType="Reference"&gt;1220407&lt;/ulink&gt;]. In June 2012, data were presented at the 48th ASCO meeting in Chicago, IL. Patients received AMG-386 at a dose of 10 mg/kg (n = 43; arm A) or 15 mg/kg (n = 42; arm B) iv qw, in combination with sunitinib (50 mg po qd) 4 weeks on and 2 weeks off. The combination treatment was well tolerated. DLTs were not observed. In arm A and arm B, the median progression-free survival was 13.9 and 16.2 months, respectively.  Progressive disease was observed in four and two patients in arm A and arm B, respectively. Favorable objective response rate was observed [&lt;ulink linkID="1295799" linkType="Reference"&gt;1295799&lt;/ulink&gt;]. In November 2015, the trial was ongoing  [&lt;ulink linkID="1220407" linkType="Reference"&gt;1220407&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2007, a randomized, double-blind, multicenter phase II trial (&lt;ulink linkID="38401" linkType="Protocol"&gt;NCT00467025&lt;/ulink&gt;; 20060159) began in patients (expected n = 150) with advanced RCC the US and Belgium. The study was to test the drug at two doses (3 and 10 mg/kg) in combination with &lt;ulink linkID="29831" linkType="Drug"&gt;sorafenib&lt;/ulink&gt;, versus sorafenib alone. At that time, the trial was expected to complete in November 2012 [&lt;ulink linkID="801350" linkType="Reference"&gt;801350&lt;/ulink&gt;], [&lt;ulink linkID="832324" linkType="Reference"&gt;832324&lt;/ulink&gt;]. Preliminary results released in November 2008 showed that the combination induced partial responses in 5 out of 17 patients evaluated [&lt;ulink linkID="960588" linkType="Reference"&gt;960588&lt;/ulink&gt;]. In February 2009, similar data were presented at the 11th International Anti-Angiogenic Agents Symposium in San Diego, CA [&lt;ulink linkID="983867" linkType="Reference"&gt;983867&lt;/ulink&gt;]. Data were published in June 2012. A total of 152 patients were randomized. PFS was 9.0, 8.5 and 9.0 months for the 10 mg/kg combination, the 3 mg/kg combination and the sorafenib monotherapy, respectively [&lt;ulink linkID="1304464" linkType="Reference"&gt;1304464&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small cell lung cancer&lt;/subtitle&gt;A non-randomized, open-label phase I/II trial (&lt;ulink linkID="90278" linkType="Protocol"&gt;NCT01666977&lt;/ulink&gt;) was initiated in August 2012 in previously untreated patients with metastatic non-squamous NSCLC to evaluate trebananib in combination with pemetrexed and carboplatin. The primary outcome measure was DLTs. The trial was to enroll 12 patients and complete in July 2019 [&lt;ulink linkID="1341524" linkType="Reference"&gt;1341524&lt;/ulink&gt;]. However, in  October 2013, Amgen announced it was discontinuing enrollment in the trial as the therapeutic landscape in NSCLC was said to limit the potential utility of trebananib in the study [&lt;ulink linkID="1493434" linkType="Reference"&gt;1493434&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Transitional cell carcinoma&lt;/subtitle&gt;In July 2013, an open-label, single-group, safety/efficacy, phase II study (&lt;ulink linkID="147410" linkType="Protocol"&gt;NCT01907308&lt;/ulink&gt;; 13-1502.cc, NCI-2013-01348) of trebananib in combination with docetaxel was expected to be initiated in December 2013 in patients (n = 38) with advanced transitional cell carcinoma of urothelial origin who failed on platinum-containing regimen in the US. At that time, the trial was expected to complete in June 2017. By April 2014, the trial was withdrawn after the sponsor decided to terminate the study [&lt;ulink linkID="1468356" linkType="Reference"&gt;1468356&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumors&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In June 2014, a phase Ib  data were presented at the 50th ASCO meeting in Chicago, IL.							 An open-label, phase Ib trial &lt;ulink linkID="161756" linkType="Protocol"&gt;(NCT01992341)&lt;/ulink&gt; evaluated the pharmacokinetic drug-drug interactions  between &lt;ulink linkID="49339" linkType="Drug"&gt;trebananib&lt;/ulink&gt; (AMG-386), angiopoietin-1 and 2 inhibitor and paclitaxel.  Out of 18 evaluable patients partial response was seen in four, stable disease in nine, progressive in five and patient showed complete response and there was no  pharmacokinetic drug-drug interactions  between trebananib and paclitaxel.[&lt;ulink linkID="1562099" linkType="Reference"&gt;1562099&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2011, a non-randomized, parallel-assignment, open-label, pharmacokinetics, phase I trial (&lt;ulink linkID="76221" linkType="Protocol"&gt;NCT01331941&lt;/ulink&gt;; 20090277) was planned in patients (expected n = 40) in the US with advanced solid tumors and normal and impaired renal function. The primary endpoints were Cmax, Tmax, Cmin, clearance and AUC from weeks 1 to 5. At that time, the trial was estimated to complete in December 2012 [&lt;ulink linkID="1220661" linkType="Reference"&gt;1220661&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 2011, an IND was accepted by the Chinese SFDA; in June 2012, supplemental material was requested to conclude the review [&lt;ulink linkID="1342685" linkType="Reference"&gt;1342685&lt;/ulink&gt;], [&lt;ulink linkID="1397528" linkType="Reference"&gt;1397528&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2009, the drug was in phase I trials in Japan [&lt;ulink linkID="1038528" linkType="Reference"&gt;1038528&lt;/ulink&gt;].  In April 2011, data from a phase I trial of trebananib (3, 10 or 30 mg/kg iv infusion, qw) in Japanese patients (n = 18) with advanced solid tumors refractory to standard therapy, were presented at the 102nd AACR meeting in Orlando, FL.   No DLTs were identified and  no anti-trebananib antibody responses were  detected. Two  patients had a confirmed partial response and two patients had stable disease   [&lt;ulink linkID="1177381" linkType="Reference"&gt;1177381&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, an open-label, non-randomized, interventional, parallel-group, dose escalation phase I trial (&lt;ulink linkID="48773" linkType="Protocol"&gt;NCT00861419&lt;/ulink&gt;; 20050170) was initiated in patients (expected n = 88) with  advanced solid tumors to assess safety, tolerability and pharmacokinetics of AMG-386  in combination with &lt;ulink linkID="49338" linkType="Drug"&gt;AMG-706&lt;/ulink&gt;, bevacizumab, sorafenib, or sunitinib. At that time, the trial was expected to complete in September 2012. In March 2013, the trial was completed [&lt;ulink linkID="1634971" linkType="Reference"&gt;1634971&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By November 2005, trebananib had entered phase I trials [&lt;ulink linkID="634908" linkType="Reference"&gt;634908&lt;/ulink&gt;]. In February 2006, clinical data on trebananib were presented at the Eighth International Anti-Angiogenic Agents Symposium in San Diego, CA. In a phase I trial in 22 patients administered with doses  from 0.3 to 30 mg/m2 trebananib, 76%  stable disease was observed. A half-life of 112 h supported a further weekly dosing schedule [&lt;ulink linkID="650448" linkType="Reference"&gt;650448&lt;/ulink&gt;]. The trial (&lt;ulink linkID="29129" linkType="Protocol"&gt;NCT00102830&lt;/ulink&gt;) was carried out in patients with advanced solid tumors [&lt;ulink linkID="677050" linkType="Reference"&gt;677050&lt;/ulink&gt;]. Similar data were presented in November 2006, at the 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Prague, Czech Republic [&lt;ulink linkID="741524" linkType="Reference"&gt;741524&lt;/ulink&gt;]. Enrollment was completed at 32 patients in October 2006, and final data were presented at the 43rd ASCO meeting in Chicago, IL, in June 2007. One DLT was seen at 30 mg/kg: respiratory arrest  deemed possibly related to trebananib. Other treatment-related toxicities were all grade 2. Pharmacokinetics were dose-linear (mean terminal half-life = 3.1 to 6.3 days). Trebananib appeared to reach a steady state after three doses, with minimal accumulation. Two patients developed binding antibodies to trebananib; in one patient, they disappeared at week 6. No neutralizing antibodies were seen. 16 patients had stable disease (median 8 weeks); 13 had progressive disease. One patient with ovarian cancer remained active at 52 weeks with 27% tumor shrinkage and  reduction in serum CA-125. A significant vascular effect (&amp;gt; 20% reduction) was seen by DCE-MRI in 7 of 12 (58%) evaluable subjects [&lt;ulink linkID="797526" linkType="Reference"&gt;797526&lt;/ulink&gt;]. In October 2008, similar clinical data were presented  at the 20th EORTC-NCI-AACR meeting in Geneva, Switzerland [&lt;ulink linkID="952542" linkType="Reference"&gt;952542&lt;/ulink&gt;]. In February 2009, similar data were presented at the 11th International Anti-Angiogenic Agents Symposium in San Diego, CA. At that time, no MTD had been reached. Fatigue and abdominal pain was observed. The recommended phase II doses were defined as 3  and 10 mg/kg [&lt;ulink linkID="983867" linkType="Reference"&gt;983867&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;OTHER STUDIES&lt;/subtitle&gt;In March 2013, pharmacokinetic data from nine clinical studies  were presented at the 114th American Society for Clinical Pharmacology and Therapeutics in Indianapolis, IN. Dose-dependent DDI were not observed with different doses of trebananib when given in combination with other chemotherapeutic agents. The PKs of chemotherapies metabolized by CYP3A4 or CYP2C8, by other enzymes, or by renal excretion were not altered when co-administered with trebananib [&lt;ulink linkID="1390099" linkType="Reference"&gt;1390099&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In April 2013, preclinical data were presented at the 104th AACR Meeting in Washington DC. Data demonstrated that both IGFR1 and IGFR2 stimulation of Akt phosphorylation were inhibited by MEDI-573 (30 microg/ml). In vitro, the human vascular endothelial cell tube formation and proliferation were inhibited by MEDI-573 (10, 20 or 30 microg/ml). MEDI-573 (30 mg/kg) demonstrated anti-angiogenic activity in mice. In vitro, the anti-angiogenic activity of MEDI-573 and the MAB-391 was prevented by IGFR1 and IGFR2, respectively. The combination of receptor binding and ligand binding antibodies showed a favorable growth of IGFR secreting pediatric sarcoma xenografts when compared with either of the agents alone. At that time, studies were ongoing to evaluate the therapeutic strategy using the xenograft models of pediatric sarcoma with characterized IGFR expression [&lt;ulink linkID="1402338" linkType="Reference"&gt;1402338&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, preclinical data were presented at the 104th AACR Meeting in Washington, DC. In DLD-1 and A431 tumor xenograft models, trebananib plus &lt;ulink linkID="12646" linkType="Drug"&gt;panitumumab&lt;/ulink&gt; combination demonstrated enhanced efficacy. Both trebananib and panitumumab monotherapies were found to reduce blood vessel area, in DLD-1 tumor xenograft model. Trebananib and panitumumab as well as panitumumab single agent  inhibited tumor cell proliferation. Tumor-associated endothelial cell proliferation in DLD-1 tumor xenografts was inhibited by trebananib alone but no such activity was shown by panitumumab alone [&lt;ulink linkID="1402335" linkType="Reference"&gt;1402335&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2013, preclinical data were presented at the 104th AACR Meeting in Washington, DC. Data showed that AMG-386 or L1-7 improved the activity of &lt;ulink linkID="12973" linkType="Drug"&gt;sunitinib&lt;/ulink&gt;, with the time to progression of 25.6, 48.2 and 51.9 days for sunitinib, sunitinib + AMG-386 and sunitinib + L1-7, respectively, in a murine RCC xenograft model of resistance to VEGFR inhibition. After the treatment with the combination, residual viable tissue was reduced. The resumption of blood flow was prevented with the tumor perfusion on day 50 post-treatment with sunitinib, sunitinib + AMG-386 and sunitinib + L1-7 were 36.7, 18.4 and 16.0 ml/100 g/min, respectively [&lt;ulink linkID="1400278" linkType="Reference"&gt;1400278&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2008, preclinical data were presented at the 99th AACR meeting in San Diego, CA.  Trebananib in combination with VEGF pathway antagonists, &lt;ulink linkID="8047" linkType="Drug"&gt;bevacizumab&lt;/ulink&gt; and &lt;ulink linkID="49338" linkType="Drug"&gt;motesanib diphosphate&lt;/ulink&gt;, enhanced antitumor activity in xenograft models of colon carcinoma [&lt;ulink linkID="893847" linkType="Reference"&gt;893847&lt;/ulink&gt;]. In October 2008, similar preclinical data were presented  at the 20th EORTC-NCI-AACR meeting in Geneva, Switzerland [&lt;ulink linkID="952542" linkType="Reference"&gt;952542&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2005, data on tie-2 receptor antagonists were presented at the 17th AACR-NCI-EORTC meeting in Philadelphia, PA. 2xCon4C, L1-7 and Ab536 demonstrated IC50 values of 0.023, 0.054 and 0.14 nM, respectively, against human Ang-2; they also showed favorable pharmacokinetics in mice, with half-lives of 97, 56 and 83 h and AUC values of 15097, 6967 and 3367 nM.h/mg/kg, respectively. Although the compounds had no effect on the growth of tumor cells in vitro, further growth of A431, Colo205 and HT29 xenografts in mice, with Ab536 dosed at 2 mg/kg twice weekly and the peptibodies at 0.6 mg/kg twice weekly, was prevented; this result was also observed when dosing was started at day 20. Tumors from treated animals showed widespread necrosis and the numbers of viable tumor cells were significantly reduced in treated-versus-control animals from two days after treatment initiation. Control animals with 45-day tumors were administered a single dose of inhibitor at 25 mg/kg and showed regression to the same volume as twice weekly-treated mice. Treatment was stopped in animals that showed a complete response, and no tumor regrowth was detected. FACS analysis showed that treatment with 2xCon4C and L1-7 suppressed endothelial cell proliferation and increased caspase-dependent apoptosis. In the rat corneal pocket model of angiogenesis, administration of 70 nM/kg doses of these peptibodies completely blocked VEGF-induced vessel formation [&lt;ulink linkID="634908" linkType="Reference"&gt;634908&lt;/ulink&gt;]. Similar data were presented at the 10th IBC Drug Discovery Technology Europe conference in March 2006 [&lt;ulink linkID="656360" linkType="Reference"&gt;656360&lt;/ulink&gt;]. In October 2008, similar preclinical data were presented  at the 20th EORTC-NCI-AACR meeting in Geneva, Switzerland [&lt;ulink linkID="952542" linkType="Reference"&gt;952542&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2004, preclinical data  on  Ang receptor antagonists were presented  at Amgen's R&amp;amp;D Day. One compound was shown to inhibit tumor growth and reduce the viable tumor fraction in preclinical models [&lt;ulink linkID="528612" linkType="reference"&gt;528612&lt;/ulink&gt;], [&lt;ulink linkID="528690" linkType="reference"&gt;528690&lt;/ulink&gt;], [&lt;ulink linkID="528696" linkType="reference"&gt;528696&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;Trebananib is engineered by fusing truncated human IgG1 Fc domain to four copies of a synthetic anti-angiopoietin peptide. The resultant molecule is a non-glycosylated protein, and its biologically active form is a covalently linked homodimer [&lt;ulink linkID="1220001" linkType="Reference"&gt;1220001&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Joel Neal &amp;amp; Heather Wakelee, &lt;ulink linkType="Company" linkID="20679"&gt;Stanford University&lt;/ulink&gt; Cancer Center, Stanford, USA&lt;/para&gt;&lt;para&gt;Submission date: 19 May 2010&lt;br/&gt;Publication date: 03 August 2010&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Abstract&lt;/subtitle&gt;The VEGF/VEGFR and angiopoietin/Tie-2 signaling pathways are important in the process of vascular endothelial growth (angiogenesis) and in the maintenance of tumor-associated blood vessels. While there are several agents targeting the VEGF/VEGFR signaling pathway, there are none available that target the angiopoietin/Tie-2 signaling pathway. The first such agent to reach clinical trials is AMG-386 (2xCon4C), being developed by &lt;ulink linkType="Company" linkID="14109"&gt;Amgen Inc&lt;/ulink&gt; and licensed in Japan to &lt;ulink linkType="Company" linkID="23215"&gt;Takeda Bio Development Center Ltd&lt;/ulink&gt;. AMG-386 is an antiangiopoietin peptibody comprising a peptide with angiopoietin-binding properties that is fused to the Fc (crystallizable fragment) region of an antibody and inhibits the interaction between the ligands angiopoietin-1 and angiopoietin-2 with the Tie-2 receptor. AMG-386 significantly inhibited the growth of tumors in a variety of mouse xenograft models. In phase I trials of AMG-386 as a monotherapy or in combination with chemotherapy in patients with advanced solid tumors, AMG-386 demonstrated only mild toxicities, and one complete response and several partial responses were achieved in patients. Phase II trials of AMG-386 in combination with chemotherapy were ongoing in a variety of solid tumors, including breast, ovarian, colorectal, gastric and renal cell cancers. If safe and effective, AMG-386 could be an exciting addition to other antiangiogenic therapies in solid tumors.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;There are many active drugs in the treatment of cancer, including traditional cytotoxic chemotherapy, and targeted therapy, including antiangiogenic therapy. Solid tumors, a subgroup of malignancies that would be predicted to respond to antiangiogenic therapy, are common in the US and are a major cause of mortality [&lt;ulink linkType="Reference" linkID="1110782"&gt;1110782&lt;/ulink&gt;]. Of the solid tumor types treatable with antiangiogenic therapy in clinical trials in 2010 in the US, breast cancer is the most common, with 209,000 new cases diagnosed and estimated to lead to 40,000 deaths. This is closely followed by colorectal cancer (143,000 new cases and 51,000 deaths), renal cell cancer (RCC; 53,000 new cases and 13,000 deaths), ovarian cancer (22,000 new cases and 14,000 deaths) and gastric cancer (21,000 new cases and 10,000 deaths) [&lt;ulink linkType="Reference" linkID="1110782"&gt;1110782&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In order for microscopic solid tumors to overcome hypoxia and to expand in tumor mass, they must support the growth of new blood vessels [&lt;ulink linkType="Reference" linkID="1106441"&gt;1106441&lt;/ulink&gt;]. Many tumors secrete molecules (eg, ligands) that support this process of angiogenesis. The downstream effects of these ligands are generally on endothelial cells. These cells, in contrast to cancer cells, are less prone to genetic alteration and the subsequent development of resistance to cancer drugs. Therefore, agents targeting angiogenesis may augment traditional anticancer therapies. The VEGF/VEGFR and angiopoietin/Tie-2 (also called angiopoietin-1 receptor) signaling pathways both promote the growth and development of tumor-associated blood vessels [&lt;ulink linkType="Reference" linkID="1106445"&gt;1106445&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106446"&gt;1106446&lt;/ulink&gt;]. Agents that target the VEGF/VEGFR pathway include the mAb &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;, which binds to soluble VEGF, and the small-molecule tyrosine kinase inhibitors &lt;ulink linkType="Drug" linkID="12973"&gt;sunitinib&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt;, which inhibit VEGFR [&lt;ulink linkType="Reference" linkID="1106446"&gt;1106446&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="8047"&gt;Bevacizumab&lt;/ulink&gt; was initially FDA-approved based on an improvement in overall survival (OS) in patients with metastatic colorectal cancer, in whom the addition of &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; to a standard combination chemotherapy backbone of &lt;ulink linkType="Drug" linkID="2871"&gt;irinotecan&lt;/ulink&gt;, bolus fluorouracil and &lt;ulink linkType="Drug" linkID="51564"&gt;leucovorin&lt;/ulink&gt; improved OS from 16 to 20 months [&lt;ulink linkType="Reference" linkID="541911"&gt;541911&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="8047"&gt;Bevacizumab&lt;/ulink&gt; was subsequently demonstrated to improve OS in metastatic NSCLC when combined with a first-line standard combination chemotherapy incorporating the microtubule inhibitor &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; and the alkylating agent &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1106448"&gt;1106448&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="8047"&gt;Bevacizumab&lt;/ulink&gt; doubled progression-free survival (PFS) to 12 months in metastatic breast cancer in combination with &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; and prolonged PFS in metastatic RCC in combination with IFNalpha [&lt;ulink linkType="Reference" linkID="865487"&gt;865487&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1102100"&gt;1102100&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="12973"&gt;Sunitinib&lt;/ulink&gt; monotherapy improved PFS in patients with RCC compared with IFNalpha monotherapy [&lt;ulink linkType="Reference" linkID="758460"&gt;758460&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106464"&gt;1106464&lt;/ulink&gt;] and improved PFS in patients with gastrointestinal stromal tumors who had failed &lt;ulink linkType="Drug" linkID="11460"&gt;imatinib&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="738325"&gt;738325&lt;/ulink&gt;]. Similarly, &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt; monotherapy has demonstrated benefits in both hepatocellular carcinoma and RCC, which are particularly refractory to traditional therapies [&lt;ulink linkType="Reference" linkID="758485"&gt;758485&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="928730"&gt;928730&lt;/ulink&gt;]. Unfortunately, despite their profound antiangiogenic effects, VEGF-inhibitor therapy generally only prolongs survival of patients with solid tumors by a few months and is associated with a range of side effects, such as bleeding, thrombosis, hypertension and palmar-plantar desquamation. A complementary approach of targeting the angiopoietin/Tie-2 signaling pathway could provide an alternative antiangiogenic therapeutic strategy for solid tumors [&lt;ulink linkType="Reference" linkID="1106475"&gt;1106475&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The angiopoietin/Tie-2 signaling pathway mediates a switch between a quiescent and an activated (ie, angiogenic) endothelium [&lt;ulink linkType="Reference" linkID="1106445"&gt;1106445&lt;/ulink&gt;]. Unlike VEGF, which appears to uniformly promote angiogenesis, the Tie-2 ligands angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) appear to have differing functions depending on endothelial cell context, with both cell-to-cell and cell-to-matrix contacts modulating the resulting signals [&lt;ulink linkType="Reference" linkID="1106475"&gt;1106475&lt;/ulink&gt;]. Tie-2 is a receptor tyrosine kinase and, generally, ligand stimulation of the receptor by Ang-1 appears to promote stabilization of a quiescent vascular endothelium; mice lacking Ang-1 or Tie-2 exhibit significant defects in angiogenesis [&lt;ulink linkType="Reference" linkID="1106482"&gt;1106482&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106485"&gt;1106485&lt;/ulink&gt;]. Ang-2 promotes vascular proliferation by disrupting Ang-1/Tie-2 signaling, allowing endothelial cells to become more responsive to growth factors, such as VEGF [&lt;ulink linkType="Reference" linkID="1106445"&gt;1106445&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106487"&gt;1106487&lt;/ulink&gt;]. Interestingly, one mechanism by which tumors may become resistant to VEGF-inhibitor treatment is through upregulation of Ang-1, resulting in protection of VEGF-dependent tumor endothelium [&lt;ulink linkType="Reference" linkID="1106489"&gt;1106489&lt;/ulink&gt;]. Therefore, agents which block Ang-2 would be predicted to disrupt the formation of tumor-associated vasculature and agents that block Ang-1 might overcome resistance to anti-VEGF therapies. This hypothesis is supported by the observation that high expression levels of Ang-2 appear to predict poor prognosis in patients with thyroid, gastric, breast, bladder and neuroendocrine cancers, and in patients with malignant melanoma [&lt;ulink linkType="Reference" linkID="1106506"&gt;1106506&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106510"&gt;1106510&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106511"&gt;1106511&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106512"&gt;1106512&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106513"&gt;1106513&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106514"&gt;1106514&lt;/ulink&gt;]. Furthermore, a variety of tumor xenografts proliferate slower in Ang-2-deficient mice compared with wild-type control mice, indicating that even host-derived Ang-2 may promote the growth of tumors [&lt;ulink linkType="Reference" linkID="1106516"&gt;1106516&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;One agent that inhibits the angiopoietin/Tie-2 signaling pathway is AMG-386, which is in development by &lt;ulink linkType="Company" linkID="14109"&gt;Amgen Inc&lt;/ulink&gt; and &lt;ulink linkType="Company" linkID="23215"&gt;Takeda Bio Development Center Ltd&lt;/ulink&gt; for various types of solid tumors [&lt;ulink linkType="Reference" linkID="1112857"&gt;1112857&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1112929"&gt;1112929&lt;/ulink&gt;]. AMG-386 is an antiangiopoietin peptibody consisting of the Fc (crystallizable fragment) region of an antibody linked to a peptide; AMG-386 directly binds to and blocks the effects of Ang-1 and Ang-2 on Tie-2 receptor signaling [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;]. At the time of publication, phase I clinical trials with AMG-386 as a monotherapy or in combination with chemotherapy had been completed and/or were ongoing; one complete response (CR) and several partial responses (PR) were achieved in patients and only mild toxicities were reported [&lt;ulink linkType="Reference" linkID="1028032"&gt;1028032&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1072980"&gt;1072980&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106520"&gt;1106520&lt;/ulink&gt;]. Phase II trials were ongoing in a variety of solid tumors, including breast, ovarian, colorectal and gastric cancer, and RCC [&lt;ulink linkType="Reference" linkID="1105066"&gt;1105066&lt;/ulink&gt;], (ClinicalTrials.gov identifiers: &lt;ulink linkType="Protocol" linkID="38401"&gt;NCT00467025&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="38301"&gt;NCT00511459&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="38300"&gt;NCT00583674&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="39258"&gt;NCT00752570&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="47602"&gt;NCT00853372&lt;/ulink&gt;, &lt;ulink linkType="Protocol" linkID="50186"&gt;NCT00872014&lt;/ulink&gt;). If safe and effective, AMG-386 could be an exciting addition to other antiangiogenic therapies in solid tumors.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;The peptide portion of AMG-386 was created by screening peptide and Fab (antigen-binding fragment) phage display libraries for Ang-2-binding peptides [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;]. Phage were bound to Ang-2-coated beads, eluted and amplified in Escherichia coli. The highest affinity Ang-2-binding peptide genes were bound to the Fc region of human IgG1 and the resulting fusion protein was expressed in E coli. The fusion product, AMG-386 (amino acid sequence: MFcGGGGGAQQEECEWDPWTCEH MGSGSATGGSGSTASSGSGSATHQEECEWDPWTCEHMLE; Fc denotes the position of the human IgG1 Fc sequence), was purified from E coli by lyzing cultures with high-pressure homogenization, and then underwent protein folding, precipitation and filtration, and two final purification steps [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical development&lt;/subtitle&gt;In an ELISA assay, AMG-386 neutralized Ang-1- and Ang-2-Tie-2 interactions; AMG-386 competitively inhibited human, mouse and rat Ang-2-Tie-2 interactions with IC50 values of 0.023, 0.021 and 0.049 nM, respectively [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;]. AMG-386 inhibited the human Ang-1-Tie-2 interaction with an IC50 value of 0.9 nM [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The in vitro growth of the human epithelial carcinoma cell line A431 was not affected by the presence of AMG-386 (6.7 microM), consistent with an effect on tumor vasculature rather than primary tumor cells [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;].In vivo, however, groups of mice bearing A431 tumor xenografts treated with AMG-386 (8, 40 or 200 microg/day sc, from post-implantation day [PID] 3 for 11 weeks) exhibited a CR rate (defined as a lack of measurable tumor) of up to 30% in a dose-independent manner. Tumors did not regrow after treatment cessation (average follow-up period was 15.3 weeks) [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;]. Similarly, in mice bearing human colon tumor (Colo205) xenografts, AMG-386 (0.024, 0.12, 0.6 or 15 mg/kg sc, biw from PID 3) dose-dependently decreased the growth of the Colo205 tumors in comparison with vehicle-control mice [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;]. When treatment of mice bearing Colo205 tumor xenografts was initiated from PID 28 rather than 3, to better replicate established disease, the viable tumor fraction was significantly reduced by AMG-386 (15 mg/kg sc, biw for 21 days) compared with vehicle-control mice. Following a further delay in treatment initiation, single doses of AMG-386 (25 mg/kg sc, on PID 45 and 116), with a long interval between doses to allow for AMG-386 clearance from the serum, led to tumor shrinkage following the first dose. This regression was sustained until day 69, at which point tumor regrowth started; the trend was repeated following the next AMG-386 dose. Moreover, in mice bearing Colo205 tumor xenografts, single-dose AMG-386 (15 mg/kg sc, on PID 28) led to a progressive reduction in endothelial cell proliferation observed between 18.5 and 48 h after dosing compared with vehicle-control mice. This was followed by a reduction in tumor cell proliferation that commenced 72 h after treatment. When the CR rate was assessed, treatment of mice bearing Colo205 tumor xenografts with a variety of AMG-386 doses and schedules (14 to 350 microg [apparently bolus], biw from PID 3 to 28 for 10 to 16 weeks) led to up to 50% of mice achieving a CR (average follow up was 15.3 weeks) [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The effects of AMG-386 on neovascularisation were assessed on two models [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106518"&gt;1106518&lt;/ulink&gt;]. Corneal angiogenesis was induced in rats by implanting VEGF (10 microM)-impregnated filter paper discs into the corneal stroma [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;]. Administration of AMG-386 (0.03, 0.1, 0.3, 1 or 10 mg/kg sc, biw, initiated 7 days prior to corneal implantation) dose-dependently reduced VEGF-mediated vessel sprouting 1 week post-implantation compared with controls. The number of blood vessels 'sprouting' also reduced towards the number observed in control corneas (treated with BSA) at the 1-mg/kg dose level [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Retinal neovascularization was induced in premature mice by hyperoxia (75% oxygen initiated on post-natal day 7 for 5 days), which causes retinal development to proceed with insufficient angiogenesis, followed by normoxia for a subsequent 5-day period, which initiates retinal neovascularization [&lt;ulink linkType="Reference" linkID="1106518"&gt;1106518&lt;/ulink&gt;]. Treatment of mice with AMG-386 (0.1, 1, 10 or 100 mg/kg sc, qd during and after or only after hyperoxia) significantly inhibited neovascularization by post-natal day 17; neovascularization was inhibited by 38, 60 and 88% in the 1-, 10- and 100-mg/kg dose groups, respectively, compared with control mice kept continuously under normoxic conditions [&lt;ulink linkType="Reference" linkID="1106518"&gt;1106518&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Additionally, the effects of inhibiting both angiogeneses pathways, VEGF/VEGFR and angiopoietin/Tie-2, were assessed [&lt;ulink linkType="Reference" linkID="893847"&gt;893847&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="952542"&gt;952542&lt;/ulink&gt;]. AMG-386 (2.8 to 14 microg sc, biw) combined with the pan-VEGFR inhibitor &lt;ulink linkType="Drug" linkID="49338"&gt;motesanib diphosphate&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="14109"&gt;Amgen&lt;/ulink&gt;/&lt;ulink linkType="Company" linkID="21991"&gt;Millennium Pharmaceuticals Inc&lt;/ulink&gt;; 37.5 to 75 mg/kg po, qd) or &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; (2.8 microg biw) had a greater antitumor effect compared with the lone agents on mice bearing HT29 (human colon adenocarcinoma) and Colo205 tumor xenografts [&lt;ulink linkType="Reference" linkID="893847"&gt;893847&lt;/ulink&gt;]. Histological examination of Colo205 tumors from the AMG-386/&lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;-treated group demonstrated significantly reduced tumor viability compared with controls. These data indicate that AMG-386 may have an additive antiangiogenic effect when combined with anti-VEGF agents [&lt;ulink linkType="Reference" linkID="893847"&gt;893847&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;Treatment of healthy rats with AMG-386 (10, 75 or 200 mg/kg sc, biw for 2 weeks) was well tolerated; a cohort of rats administered a further dose on day 29 and necropsied on day 57 was assessed during dosing and at necropsy for body weight, food consumption, hematology, and clinical and urine analyses, and no significant adverse effects were observed [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;]. In the 75- and 200-mg/kg dose cohorts, an effect of treatment was observed on the thickness of the epiphyseal growth plate, which was reversed when treatment was withdrawn for 1 month; this effect was deemed a consequence of antiangiogenic therapy in growing rats that was unlikely to occur in adult rats [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In mice bearing A431 or Colo205 tumor xenografts, treatment with AMG-386 (8 mg/kg sc, qd or 14 mg/kg sc, biw for 11 weeks) resulted in no abnormality in hematological parameters or serum chemistry values, and no histological changes in major organs were observed at necropsy [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Combinations of AMG-386 (2.8 to 14 microg sc, biw) with &lt;ulink linkType="Drug" linkID="49338"&gt;motesanib diphosphate&lt;/ulink&gt; (37.5 to 75 mg/kg po, qd) or &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; (2.8 microg biw) were well tolerated by mice bearing HT29 or Colo205 tumor xenografts and did not lead to body weight loss [&lt;ulink linkType="Reference" linkID="893847"&gt;893847&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and pharmacokinetics&lt;/subtitle&gt;The pharmacokinetics of single-dose AMG-386 was investigated in healthy mice (50 microg sc) and rats (1 to 4 mg/kg sc). AMG-386 administered to mice and rats exhibited t1/2 values of 97 and 85 h, respectively, supporting daily to weekly subcutaneous administration. The AUCinfinity values, normalized to a 1-mg/kg dose, were 15,097 and 8733 nM.h/mg/kg in mice and rats, respectively [&lt;ulink linkType="Reference" linkID="1078023"&gt;1078023&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase I, first-in-human clinical trial (&lt;ulink linkType="Protocol" linkID="29129"&gt;NCT00102830&lt;/ulink&gt;; 20040169) that assessed AMG-386 (0.3 to 30 mg/kg iv, qw for 4 weeks) in patients (n = 32) with advanced solid tumors, serum levels of AMG-386 increased dose-dependently and appeared to reach steady-state at 4 weeks [&lt;ulink linkType="Reference" linkID="797526"&gt;797526&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1028032"&gt;1028032&lt;/ulink&gt;]. After the 4-week dose, mean Cmax values ranged from 9.27 to 846 microg/ml, mean Cmin values ranged from 0.4 to 48 microg/ml, mean AUC0-t (time zero to the time of the dosing interval) values ranged from 279 to 27,300 microg.h/ml and mean terminal-phase elimination t1/2 values ranged from 3.1 to 6.3 days. The volume of distribution at steady-state and the clearance rate were similar across each dose level and ranged from 79.8 to 110 ml/kg and 0.70 to 1.27 ml/h/kg, respectively [&lt;ulink linkType="Reference" linkID="1028032"&gt;1028032&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In a phase Ib clinical trial that assessed AMG-386 (10 mg/kg iv, qw) in combination with three standard chemotherapy regimens (&lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; or FOLFOX-4 [&lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt;, 5-fluorouracil and &lt;ulink linkType="Drug" linkID="51564"&gt;leucovorin&lt;/ulink&gt;]), steady-state was reached after four AMG-386 infusions [&lt;ulink linkType="Reference" linkID="1072979"&gt;1072979&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1078018"&gt;1078018&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106520"&gt;1106520&lt;/ulink&gt;]. The Cmax, AUC0-t and clearance values of AMG-386 determined after four AMG-386 infusions were similar across chemotherapy cohorts; the combined mean Cmax, AUC0-t and clearance values were 219 microg/ml, 8120 microg.h/ml and 1.08 ml/h/kg, respectively. The combined mean terminal t1/2 value ranged from 80.8 to 99 h. No pharmacokinetic interactions between AMG-386 and the chemotherapy regimens were observed. During the trial period, no effects on AMG-386 serum concentration or pharmacokinetic parameters were noted in patients who had tested positive for non-neutralizing antibodies against AMG-386 at week 1 [&lt;ulink linkType="Reference" linkID="1106520"&gt;1106520&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In interim reports from a phase I (&lt;ulink linkType="Protocol" linkID="48773"&gt;NCT00861419&lt;/ulink&gt;; 20050170) and a phase Ib (&lt;ulink linkType="Protocol" linkID="35967"&gt;NCT00770536&lt;/ulink&gt;; 20070182) clinical trial assessing combinations of AMG-386 with &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="49338"&gt;motesanib diphosphate&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt; in patients (n = 46) with advanced solid tumors, and AMG-386 with &lt;ulink linkType="Drug" linkID="4577"&gt;topotecan&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="7934"&gt;pegylated liposomal doxorubicin&lt;/ulink&gt; in patients (expected n = 100) with ovarian cancer, respectively, pharmacokinetic parameters of the agents were unaffected by the treatment combinations [&lt;ulink linkType="Reference" linkID="1072980"&gt;1072980&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106526"&gt;1106526&lt;/ulink&gt;]. It was further reported that the presence of non-neutralizing antibodies against AMG-386 did not appear to affect AMG-386 exposure [&lt;ulink linkType="Reference" linkID="1072980"&gt;1072980&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Interim pharmacokinetic data from a phase II clinical trial (&lt;ulink linkType="Protocol" linkID="38361"&gt;NCT00479817&lt;/ulink&gt;; 20060342) that was assessing AMG-386 (3 or 10 mg/kg iv, qw) with &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; in patients (n = 161) with advanced ovarian cancer demonstrated dose-proportional AMG-386 Cmax and Cmin values that were similar to those observed in the phase I monotherapy trial [&lt;ulink linkType="Reference" linkID="1105066"&gt;1105066&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A population pharmacokinetic/pharmacodynamic analysis was undertaken using data from the phase I, first-in-human clinical trial that assessed AMG-386 in patients with advanced solid tumors combined with data from the phase II trialassessing AMG-386 with or without &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt;. A COX regression analysis indicated a significantly longer PFS in the 10-mg/kg cohort and in patients who had an increased AUCss [&lt;ulink linkType="Reference" linkID="1106521"&gt;1106521&lt;/ulink&gt;]. Patients with an AUCss value &gt;/= 9.6 mg.h/ml had a longer PFS (8.1 months) compared with patients with an AUCss value &amp;lt; 9.6 mg.h/ml (5.7 months) and patients receiving placebo (4.6 months). A parametric survival model-based simulation was used to estimate the maximal benefit in PFS in patients with ovarian cancer. A weekly infusion of 15 mg/kg AMG-386 (equivalent to an AUCss value of &gt;/= 9.6 mg.h/ml in &amp;gt; 90% of patients) was estimated to provide a median PFS of 8.3 months compared with 5 months for placebo [&lt;ulink linkType="Reference" linkID="1106521"&gt;1106521&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;A phase I, first-in-human, non-randomized, dose-escalation, open-label, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="29129"&gt;NCT00102830&lt;/ulink&gt;; 20040169) assessed AMG-386 (0.3, 1, 3, 10 or 30 mg/kg iv, qw for 4 weeks) in patients (n = 32) with advanced solid tumors [&lt;ulink linkType="Reference" linkID="741524"&gt;741524&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="797526"&gt;797526&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1028032"&gt;1028032&lt;/ulink&gt;]. Of 29 patients who were evaluable for tumor response (defined by the response evaluation criteria in solid tumors; RECIST), 1 patient achieved a PR, 16 achieved stable disease, while 12 had progressive disease. Patients (n = 4) with stable disease for &amp;gt; 4 months had soft tissue sarcoma, thyroid cancer, pseudomyxoma or submandibular adenocarcinoma that was stable for 191, 135, 246 and 247 days, respectively. One patient with ovarian cancer achieved a PR after 68 weeks of continuous treatment, with a corresponding reduction from baseline in serum cancer antigen 125 (CA-125; an ovarian cancer biomarker) levels. The serum CA-125 levels were 217 U/ml at baseline, 73 U/ml following 4 weeks of treatment and remained between 20 to 40 U/ml for &amp;gt; 2 years; this patient withdrew from the trial with a PR after 156 weeks of treatment. In an analysis of tumor blood flow and vascular permeability with correlative dynamic contrast enhanced-MRI, decreases in the blood volume transfer constant (Ktrans) and in the initial area under the uptake curve (IAUC) values were demonstrated, indicating that AMG-386 impacts tumor blood flow and vascular permeability. In the 30-mg/kg AMG-386 cohort, significant reductions in the median Ktrans and IAUC values from baseline were observed in analyses at 48 h (20.3 and 19.4%, respectively) and 8 weeks (31.5 and 28.9%, respectively) [&lt;ulink linkType="Reference" linkID="1028032"&gt;1028032&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase Ib, non-randomized, open-label, multicenter clinical trial assessed AMG-386 (10 mg/kg iv, qw) in combination with three standard chemotherapy regimens (&lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; or FOLFOX-4) in patients (n = 26) with advanced solid tumors [&lt;ulink linkType="Reference" linkID="1072979"&gt;1072979&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1078018"&gt;1078018&lt;/ulink&gt;] [&lt;ulink linkType="Reference" linkID="1106520"&gt;1106520&lt;/ulink&gt;]. Patients received one cycle of chemotherapy followed by chemotherapy plus AMG-386. Of the patients (n = 22) who received AMG-386 (median of 14 doses), seven received &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; (6/200 mg/ml.miniv on day 1 of a 3-week cycle; median of 6 cycles), nine received &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; (75 mg/m2 iv on day 1 of a 3-week cycle; median of 6 cycles) and six received FOLFOX-4 (85 mg/m2 iv &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt;, 200 mg/m2 iv &lt;ulink linkType="Drug" linkID="51564"&gt;leucovorin&lt;/ulink&gt;, 400 mg/m2 5-fluorouracil iv bolus and 600 mg/m2 5-fluorouracil iv continuous on day 1 and 200 mg/m2 iv &lt;ulink linkType="Drug" linkID="51564"&gt;leucovorin&lt;/ulink&gt;, 400 mg/m2 5-fluorouracil iv bolus and 600 mg/m2 5-fluorouracil iv continuous on day 2 of a 2-week cycle; median of 26, 13 and 6.5 cycles of 5-fluorouracil, &lt;ulink linkType="Drug" linkID="51564"&gt;leucovorin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="3792"&gt;oxaliplatin&lt;/ulink&gt;). Of 18 patients who were evaluable for tumor response (defined by RECIST), 1 patient with bladder cancer (in the &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; cohort) achieved a CR, 3 patients achieveda PR (1 patient with pancreatic, prostate and breast cancer in each of the FOLFOX-4, &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt;/paclitaxelcohorts, respectively) and 13 patients achieved stable disease (3, 4 and 6 patients in the FOLFOX-4, &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; cohorts, respectively). A reduction in tumor size from baseline was achieved by 14 patients, with a reduction of &amp;gt; 10% achieved by 12 patients [&lt;ulink linkType="Reference" linkID="1106520"&gt;1106520&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I, non-randomized, dose-escalation, open-label, uncontrolled, single-group-assignment, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="48773"&gt;NCT00861419&lt;/ulink&gt;; 20050170) in patients (n = 46) with advanced solid tumors was assessing AMG-386 (3 or 10 mg/kg iv, qw) in combination with &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt; (15 mg/kg iv, biw), &lt;ulink linkType="Drug" linkID="49338"&gt;motesanib diphosphate&lt;/ulink&gt; (75 or 125 mg po, qd) or &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt; (400 mg po, bid) [&lt;ulink linkType="Reference" linkID="1072980"&gt;1072980&lt;/ulink&gt;]. In interim results, disclosed from evaluable patients (n = 46) who had received &gt;/= 1 dose of AMG-386, five patients achieved a PR (2 with &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;, 1 with &lt;ulink linkType="Drug" linkID="49338"&gt;motesanib diphosphate&lt;/ulink&gt; and 2 with &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt;) ranging from 16 to 76 weeks. Stable disease was achieved by 23 patients (14 with &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;, 4 with &lt;ulink linkType="Drug" linkID="49338"&gt;motesanib diphosphate&lt;/ulink&gt; and 5 with &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt;); of these, nine patients had stable disease for &amp;gt; 6 months. Progressive disease was observed in nine patients [&lt;ulink linkType="Reference" linkID="1072980"&gt;1072980&lt;/ulink&gt;]. This trial was ongoing, but no longer recruiting patients, at the time of publication and had an estimated completion date of January 2011.&lt;/para&gt;&lt;para&gt;A phase Ib, non-randomized, open-label, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="35967"&gt;NCT00770536&lt;/ulink&gt;; 20070182) was assessing AMG-386 (10 mg/kg iv, qw, with optional dose de-escalation to 3 mg/kg depending on the occurrence of DLT) in combination with &lt;ulink linkType="Drug" linkID="7934"&gt;pegylated liposomal doxorubicin&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="4577"&gt;topotecan&lt;/ulink&gt; in patients (expected n = 100) with recurrent epithelial ovarian cancer [&lt;ulink linkType="Reference" linkID="1106526"&gt;1106526&lt;/ulink&gt;]. In an interim report from evaluable patients (n = 6 with &lt;ulink linkType="Drug" linkID="7934"&gt;pegylated liposomal doxorubicin&lt;/ulink&gt; and n = 6 with &lt;ulink linkType="Drug" linkID="4577"&gt;topotecan&lt;/ulink&gt;) with &gt;/= 4 weeks follow-up, there was no dose de-escalation because of DLTs. Tumor responses (defined by RECIST) observed were PFS achieved by eight patients, while three patients had progressive disease and one patient died of progressive disease. There was a response in CA-125 levels in six patients and one patient had progression in CA-125 levels [&lt;ulink linkType="Reference" linkID="1106526"&gt;1106526&lt;/ulink&gt;]. This trial was recruiting patients at the time of publication and had an estimated completion date of November 2011.&lt;/para&gt;&lt;para&gt;A further phase Ib, non-randomized, open-label, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="38484"&gt;NCT00807859&lt;/ulink&gt;; 20062042) was recruiting patients at the time of publication. This trial was to assess AMG-386 (10 mg/kg iv, qw with dose de-escalation to 3 mg/kg) in combination with either &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="6386"&gt;trastuzumab&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="33591"&gt;lapatinib&lt;/ulink&gt; in patients (expected n = 40) with locally recurrent or metastatic EGFR2-positive breast cancer. The primary objective of the trial was the safety and tolerability of the combinations. The trial had an estimated completion date of October.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;A phase II, randomized, double-blind, placebo-controlled, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="38361"&gt;NCT00479817&lt;/ulink&gt;; 20060342) was assessing AMG-386 (3 or 10 mg/kg iv, qw) in combination with &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; (80 mg/m2 iv, qw) in patients (n = 161) with advanced recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer [&lt;ulink linkType="Reference" linkID="1105066"&gt;1105066&lt;/ulink&gt;]. In an interim report, the median PFS rate was 7.2 and 5.7 months in the 10- and 3-mg/kg AMG-386 plus &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; cohorts, respectively, compared with 4.6 months in a control group that received &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; plus a placebo. The objective response rate (defined by RECIST as CR + PR) was 37 and 19%, and the CA-125 response rate was 71 and 58%, in the 10- and 3-mg/kg AMG-386 plus &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; cohorts, respectively, compared with 27% (objective response rate) and 28% (CA-125 response rate) in the placebo/&lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; cohort [&lt;ulink linkType="Reference" linkID="1105066"&gt;1105066&lt;/ulink&gt;]. This trial was ongoing, but no longer recruiting patients, at the time of publication and had an estimated completion date of April 2013.&lt;/para&gt;&lt;para&gt;At the time of publication, several further phase II clinical trials were ongoing. In a phase II, randomized, double-blind, placebo-controlled, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="38300"&gt;NCT00583674&lt;/ulink&gt;; 20060439), patients (expected n = 171) with metastatic gastric, gastroesophageal junction or distal esophageal adenocarcinoma were to receive AMG-386 (3 or 10 mg/kg iv, qw) or placebo in combination with cisplatin and &lt;ulink linkType="Drug" linkID="12205"&gt;capecitabine&lt;/ulink&gt;. The primary objective was to determine the PFS of the individual arms. This trial was no longer recruiting patients and had an estimated completion date of July 2013.&lt;/para&gt;&lt;para&gt;In a phase II, four-arm, randomized, placebo-controlled, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="38301"&gt;NCT00511459&lt;/ulink&gt;; 20060341), patients (expected n = 220) with EGFR2-negative, metastatic or locally recurrent breast cancer were to receive AMG-386 (3 or 10 mg/kg iv, qw) or placebo in combination with &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; plus &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;. The primary objective was to determine the PFS of the individual arms. This trial was no longer recruiting patients and had an estimated completion date of September 2012.&lt;/para&gt;&lt;para&gt;In a phase II, randomized, double-blind, placebo-controlled, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="38401"&gt;NCT00467025&lt;/ulink&gt;; 20060159), patients (expected n = 150) with previously untreated RCC were to receive AMG-386 (3 or 10 mg/kg iv, qw) in combination with &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt;. The primary objective was the safety and tolerability of the combination. This trial was no longer recruiting patients and had an estimated completion date of November 2012.&lt;/para&gt;&lt;para&gt;In a phase II, randomized, double-blind, placebo-controlled, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="39258"&gt;NCT00752570&lt;/ulink&gt;; 20070307), patients (expected n = 138) with previously treated metastatic colorectal carcinoma were to receive AMG-386 (10 mg/kg iv, qw) or placebo in combination with 5-fluorouracil, &lt;ulink linkType="Drug" linkID="51564"&gt;leucovorin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="2871"&gt;irinotecan&lt;/ulink&gt; (FOLFIRI). The primary objective was to determine the PFS of the individual arms. This trial was recruiting patients and had an estimated completion date of February 2013.&lt;/para&gt;&lt;para&gt;In a phase II, non-randomized, open-label, uncontrolled, single-group-assignment, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="50186"&gt;NCT00872014&lt;/ulink&gt;; 20080580), patients (expected n = 30) with advanced or inoperable hepatocellular cancer were to receive AMG-386 (10 mg/kg iv, qw) plus &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt;. The primary objective was to determine the time to progression of the cohort. This trial was recruiting patients and had an estimated completion date of May 2015.&lt;/para&gt;&lt;para&gt;In a phase II, four-arm, open-label, multicenter clinical trial (&lt;ulink linkType="Protocol" linkID="47602"&gt;NCT00853372&lt;/ulink&gt;; 20080579), patients (expected n = 80) with RCC were to receive AMG-386 (10 or 15 mg/kg iv, qw) with or without &lt;ulink linkType="Drug" linkID="12973"&gt;sunitinib&lt;/ulink&gt;. The primary objective was the safety and tolerability of the combination. This trial was recruiting patients and had an estimated completion date of May 2015.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and contraindications&lt;/subtitle&gt;In the phase I, first-in-human clinical trial (&lt;ulink linkType="Protocol" linkID="29129"&gt;NCT00102830&lt;/ulink&gt;; 20040169), AMG-386 treatment was well tolerated and an MTD was not reached [&lt;ulink linkType="Reference" linkID="741524"&gt;741524&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="797526"&gt;797526&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1028032"&gt;1028032&lt;/ulink&gt;]. Treatment-related toxicities were reported by 50% of patients. The most common treatment-related toxicities, occurring in &gt;/= 5 patients, were grade 1 and 2 fatigue (25%) and peripheral edema (13%). Grade 2 or 3 proteinuria was observed in 34% of patients; proteinuria resolved spontaneously after 1 to 2 weeks and no patients discontinued the trial as a result. A DLT was observed in one patient with a carcinoma of unknown origin who died of respiratory failure after two doses of AMG-386 at 30 mg/kg. The patient had extensive metastatic disease in multiple organs and death was deemed related to tumor burden, with a possible contribution of AMG-386 therapy. Serum samples from patients were evaluated for the presence of antibodies against AMG-386 at baseline (before dosing) and at treatment weeks 1, 2, 4, 6 and every 4 weeks thereafter, and approximately 4 weeks after the final AMG-386 dose. During treatment, non-neutralizing antibodies against AMG-386 were developed by two patients. The response was transient in one patient and subsequent serum samples were unavailable for analysis from the second. Pre-existing non-neutralizing antibodies against AMG-386 were detected in one patient but were not detected in subsequent testing. Neutralizing antibodies against AMG-386 were not detected in the serum from any patients at any time point [&lt;ulink linkType="Reference" linkID="1028032"&gt;1028032&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase Ib clinical trial that assessed AMG-386 in combination with three standard chemotherapy regimens, no DLT (defined as &amp;gt; grade 3 hematological or nonhematological toxicity occurring within 28 days of AMG-386-treatment initiation) to treatment was observed [&lt;ulink linkType="Reference" linkID="1072979"&gt;1072979&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1078018"&gt;1078018&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1106520"&gt;1106520&lt;/ulink&gt;]. Grade 3 serious adverse events, deemed to be possibly related to AMG-386 therapy, were observed in the AMG-386-&lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; cohort and included pulmonary embolism (n = 1)and jugular vein thrombosis (n = 1). Adverse events that were considered to be related to AMG-386 therapy were &amp;lt;/= grade 2 and occurred in 45% of the evaluable AMG-386-treated patients (n = 22 of 26; 4 patients had discontinued the trial because of chemotherapy-related adverse events prior to the commencement of AMG-386 therapy). The most commonly reported adverse events in the AMG-386 plus &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt;/&lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="2953"&gt;docetaxel&lt;/ulink&gt; or FOLFOX-4 cohorts were diarrhea (14, 22 and 0%, respectively), hypomagnesemia (0, 11 and 33%, respectively) and hypokalemia (0, 0 and 33%, respectively); the remainder of the adverse events were mainly reported by individual patients in the AMG-386 plus FOLFOX-4 cohort and included stomatitis, malaise, peripheral edema, hyperglycemia, pain in an extremity, alopecia, erythematous rash, skin discoloration, urticaria and flushing. Serum samples from patients (n = 21) were evaluated for the presence of antibodies against AMG-386 at baseline and at treatment weeks 1, 2, 4, 8 and every 4 weeks thereafter until trial completion. At week 1, one patient had developed non-neutralizing antibodies against AMG-386, and one patient had pre-existing non-neutralizing antibodies against AMG-386, but was negative for antibodies against AMG-386 in subsequent tests [&lt;ulink linkType="Reference" linkID="1106520"&gt;1106520&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In interim safety data from the phase Ib clinical trial (&lt;ulink linkType="Protocol" linkID="48773"&gt;NCT00861419&lt;/ulink&gt;; 20050170) that assessed AMG-386 in combination with &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="49338"&gt;motesanib diphosphate&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt;, 61% of patients experienced a treatment-related adverse event (52, 55 and 90% with &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="49338"&gt;motesanib diphosphate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt;, respectively) and the majority (82%) were &amp;lt;/= grade 2 [&lt;ulink linkType="Reference" linkID="1072980"&gt;1072980&lt;/ulink&gt;]. Treatment-related adverse events &gt;/= grade 3 were reported by 8, 9 and 20% of &lt;ulink linkType="Drug" linkID="8047"&gt;bevacizumab&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="49338"&gt;motesanib diphosphate&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="29831"&gt;sorafenib&lt;/ulink&gt; cohorts, respectively. The most common adverse events were diarrhea, weight loss, hypophosphate, proteinuria, rash, hypertension and hemorrhage; two hemorrhagic events, deemed to be possibly related to AMG-386 therapy, led to the death of two patients with squamous cell head and neck cancer. Non-neutralizing antibodies against AMG-386 were detected in 36% of the patients evaluated (n = 36) [&lt;ulink linkType="Reference" linkID="1072980"&gt;1072980&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In interim safety data from the phase Ib clinical trial (&lt;ulink linkType="Protocol" linkID="35967"&gt;NCT00770536&lt;/ulink&gt;; 20070182) that assessed AMG-386 in combination with &lt;ulink linkType="Drug" linkID="7934"&gt;pegylated liposomal doxorubicin&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="4577"&gt;topotecan&lt;/ulink&gt;, 11 of 12 evaluable patients reported treatment-related adverse events (n = 6 and 5 with &lt;ulink linkType="Drug" linkID="7934"&gt;pegylated liposomal doxorubicin&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4577"&gt;topotecan&lt;/ulink&gt;, respectively), of which 5 were grade 3 [&lt;ulink linkType="Reference" linkID="1106526"&gt;1106526&lt;/ulink&gt;]. The most common treatment-related adverse events were nausea, fatigue, rash and anemia [&lt;ulink linkType="Reference" linkID="1106526"&gt;1106526&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In interim safety data from the phase II clinical trial (&lt;ulink linkType="Protocol" linkID="38361"&gt;NCT00479817&lt;/ulink&gt;; 20060342) that assessed AMG-386 in combination with &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt;, adverse events were more common in the combination treatment arms compared with placebo/&lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; and included &gt;/= grade 3 peripheral edema, hypokalemia and thrombotic events [&lt;ulink linkType="Reference" linkID="1105066"&gt;1105066&lt;/ulink&gt;]. Other events that would be typical of VEGF-inhibitor toxicity, such as bowel perforation, hypertension, thromboembolism, proteinuria, cardiac toxicity and hemorrhage, were not commonly reported. Non-neutralizing antibodies against AMG-386 were detected in three of the patients evaluated (n = 92) [&lt;ulink linkType="Reference" linkID="1105066"&gt;1105066&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the population pharmacokinetic/pharmacodynamic analysis using data from the phase I, first-in-human clinical trial and the phase II trial, no correlation was observed between AUCss and safety parameters [&lt;ulink linkType="Reference" linkID="1106521"&gt;1106521&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent summary&lt;/subtitle&gt;&lt;ulink linkType="Patent" linkID="PA2865025"&gt;WO-03057134&lt;/ulink&gt; appears to contain the earliest claims from &lt;ulink linkType="Company" linkID="14109"&gt;Amgen&lt;/ulink&gt; relating to AMG-386, disclosing peptides that bind to Ang-2 and peptibodies comprising those peptides (see claims 41 and 66) for the treatment of angiogenesis-related disorders, such as cancer. &lt;ulink linkType="Patent" linkID="PA2865025"&gt;WO-03057134&lt;/ulink&gt; was granted as &lt;ulink linkType="Patent" linkID="PA3482994"&gt;US-07666839&lt;/ulink&gt; (expiring in March 2024), &lt;ulink linkType="Patent" linkID="PA3492555"&gt;US-07666832&lt;/ulink&gt; (expiring in March 2024), &lt;ulink linkType="Patent" linkID="PA3492554"&gt;US-07666831&lt;/ulink&gt; (expiring in April 2024), &lt;ulink linkType="Patent" linkID="PA3176038"&gt;US-07138370&lt;/ulink&gt; (expiring in June 2024), &lt;ulink linkType="Patent" linkID="PA3177211"&gt;US-07205275&lt;/ulink&gt; (expiring in September 2024) and &lt;ulink linkType="Patent" linkID="PA3203177"&gt;US-07723499&lt;/ulink&gt; (expiring in March 2025) in the US. In Europe, &lt;ulink linkType="Patent" linkID="PA2865025"&gt;WO-03057134&lt;/ulink&gt; was granted as EP-01434791 (expiring in October 2022).&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Patent" linkID="PA2914961"&gt;WO-2004092215&lt;/ulink&gt;, from the same team of inventors, claims the use of specific Ang-2-binding peptibodies, likely including AMG-386, for treating inflammatory diseases. Subsequent claims from the company that appear to relate to the candidate include (i) &lt;ulink linkType="Patent" linkID="PA3173132"&gt;WO-2006036834&lt;/ulink&gt;, claiming compositions comprising modified Fc-region domains linked to peptides that act as Ang-2-binding agents; (ii) &lt;ulink linkType="Patent" linkID="PA3531578"&gt;WO-2007089445&lt;/ulink&gt;, claiming combinations comprising Ang-2 inhibitors, such as AMG-386, and a VEGF inhibitor; (iii) &lt;ulink linkType="Patent" linkID="PA3562016"&gt;WO-2007124090&lt;/ulink&gt;, claiming lyophilized peptibody formulations where the peptibody is an Ang-2 inhibitor; (iv) &lt;ulink linkType="Patent" linkID="PA3753351"&gt;WO-2009026122&lt;/ulink&gt;, claiming formulations of antibodies and Fc-fusion molecules using polycations; (v) &lt;ulink linkType="Patent" linkID="PA5355703"&gt;WO-2009105269&lt;/ulink&gt;, claiming antibodies directed to Ang-1 and Ang-2; and (vi) &lt;ulink linkType="Patent" linkID="PA5467975"&gt;WO-2009158432&lt;/ulink&gt;, claiming the use of Ang-2 inhibitors, such as AMG-386, for the treatment of multiple sclerosis.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current opinion&lt;/subtitle&gt;Inhibition of tumor angiogenesis remains an attractive strategy to restrict the growth of tumors. Angiogenesis inhibitors may be more broadly active and safer than conventional chemotherapy. By inhibiting proliferation of the healthy endothelium and not targeting the tumor itself, these agents may circumvent the development of drug resistance or inadequate drug delivery. Inhibitors of the VEGF/VEGFR signaling pathway have successfully prolonged the survival of patients with solid tumors, but are associated with several side effects.&lt;/para&gt;&lt;para&gt;The AMG-386 peptibody inhibits the angiopoietin/Tie-2 signaling pathway and blocks angiogenesis in a manner distinct from VEGF/VEGFR inhibitors. AMG-386 is most likely to demonstrate efficacy in cancers that are also sensitive to VEGF/VEGFR inhibition, such as RCC, lung, colorectal and breast cancer. However, as the response to VEGF/VEGFR inhibition usually lasts only a few months in patients, it is possible that the addition of AMG-386 to VEGF inhibitors will further restrict angiogenesis and help lengthen the time of these responses. Also, as healthy endothelial cells should be relatively refractory to the development of resistance, AMG-386 may augment conventional chemotherapy-based strategies to combat solid tumors.&lt;/para&gt;&lt;para&gt;Several other drug candidates are being investigated that target the angiopoietin/Tie-2 signaling pathway. These include a series of imidazole-vinyl-pyrimidines (&lt;ulink linkType="Company" linkID="14190"&gt;AstraZeneca plc&lt;/ulink&gt;), which inhibited the Tie-2 receptor at high nanomolar to low micromolar concentrations in vitro [&lt;ulink linkType="Reference" linkID="955710"&gt;955710&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1110871"&gt;1110871&lt;/ulink&gt;] and &lt;ulink linkType="Drug" linkID="63043"&gt;CGEN-25017&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="27293"&gt;Compugen Ltd&lt;/ulink&gt;), which inhibited angiogenesis in preclinical models [&lt;ulink linkType="Reference" linkID="997147"&gt;997147&lt;/ulink&gt;]. Both these therapies are still in the early stages of investigation. The only other molecule that is being assessed in clinical trials is &lt;ulink linkType="Drug" linkID="57800"&gt;ARRY-614&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="25902"&gt;Array Biopharma Inc&lt;/ulink&gt;), an inhibitor of both p38 MAPK and Tie-2 kinase [&lt;ulink linkType="Reference" linkID="732986"&gt;732986&lt;/ulink&gt;], for which a phase I trial began in March 2008 in healthy volunteers [&lt;ulink linkType="Reference" linkID="889006"&gt;889006&lt;/ulink&gt;]. No results were available for &lt;ulink linkType="Drug" linkID="57800"&gt;ARRY-614&lt;/ulink&gt; at the time of publication. Thus AMG-386, which was being assessed in phase II trials and for which a phase III program in patients with ovarian cancer began in March 2010 [&lt;ulink linkType="Reference" linkID="1096272"&gt;1096272&lt;/ulink&gt;], is the most advanced angiopoietin/Tie-2-signaling inhibitor in development. The results with AMG-386 to date are encouraging and data from ongoing trials are eagerly awaited. Hopefully, angiopoietin/Tie-2-signaling inhibitors will eventually allow the realization of the late Judah Folkman's vision: to turn cancer into a chronic disease by preventingangiogenesis [&lt;ulink linkType="Reference" linkID="1106441"&gt;1106441&lt;/ulink&gt;].&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2016-06-27T00:00:00.000Z</StatusDate><Source id="1775723" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3866">Metastatic ovary cancer</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1736448" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2016-06-27T00:00:00.000Z</StatusDate><Source id="1775723" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1736448" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3866">Metastatic ovary cancer</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1736448" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1736448" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2016-06-27T00:00:00.000Z</StatusDate><Source id="1775723" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1736448" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1736448" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1736448" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3866">Metastatic ovary cancer</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1736448" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1736448" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2013-10-22T00:00:00.000Z</StatusDate><Source id="1493434" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1736448" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="3866">Metastatic ovary cancer</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1736448" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1736448" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1736448" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1736448" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="2">Lack of Activity or Efficacy</DiscontinuedReason><Indication id="799">Ovary tumor</Indication><StatusDate>2016-02-09T00:00:00.000Z</StatusDate><Source id="1736448" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2016-02-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2016-02-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate>2016-02-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1771">Transitional cell carcinoma</Indication><StatusDate>2015-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2016-02-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3467">Metastatic renal cancer</Indication><StatusDate>2016-02-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3467">Metastatic renal cancer</Indication><StatusDate>2016-02-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2016-02-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2016-02-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2016-02-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3460">Metastatic gastrointestinal cancer</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3667">Metastatic esophageal cancer</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2016-10-30T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2016-02-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2016-02-16T00:00:00.000Z</StatusDate><Source id="1342685" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2016-02-16T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="131">Gastrointestinal tumor</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="14109">Amgen Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3460">Metastatic gastrointestinal cancer</Indication><StatusDate>2013-12-31T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1262">Non-small-cell lung cancer</Indication><StatusDate>2012-03-21T00:00:00.000Z</StatusDate><Source id="1267859" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="131">Gastrointestinal tumor</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="882094" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3460">Metastatic gastrointestinal cancer</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="882094" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3460">Metastatic gastrointestinal cancer</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="882094" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="989">Colorectal tumor</Indication><StatusDate>2008-11-19T00:00:00.000Z</StatusDate><Source id="1086208" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3667">Metastatic esophageal cancer</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="882094" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2007-09-06T00:00:00.000Z</StatusDate><Source id="809143" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3866">Metastatic ovary cancer</Indication><StatusDate>2011-09-16T00:00:00.000Z</StatusDate><Source id="1296216" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2011-04-28T00:00:00.000Z</StatusDate><Source id="1220001" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3866">Metastatic ovary cancer</Indication><StatusDate>2011-09-16T00:00:00.000Z</StatusDate><Source id="1296216" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2010-03-10T00:00:00.000Z</StatusDate><Source id="1096272" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3866">Metastatic ovary cancer</Indication><StatusDate>2011-09-16T00:00:00.000Z</StatusDate><Source id="1296216" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2011-04-28T00:00:00.000Z</StatusDate><Source id="1220001" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3866">Metastatic ovary cancer</Indication><StatusDate>2011-09-16T00:00:00.000Z</StatusDate><Source id="1296216" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2011-04-28T00:00:00.000Z</StatusDate><Source id="1220001" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="CL">Chile</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="MX">Mexico</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2010-12-02T00:00:00.000Z</StatusDate><Source id="1137669" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23215">Takeda Bio Development Center Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2015-04-30T00:00:00.000Z</StatusDate><Source id="1688729" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2012-08-31T00:00:00.000Z</StatusDate><Source id="1341524" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1771">Transitional cell carcinoma</Indication><StatusDate>2013-07-18T00:00:00.000Z</StatusDate><Source id="1468356" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2007-09-13T00:00:00.000Z</StatusDate><Source id="824548" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2009-08-03T00:00:00.000Z</StatusDate><Source id="1220037" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2007-09-13T00:00:00.000Z</StatusDate><Source id="824548" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3467">Metastatic renal cancer</Indication><StatusDate>2007-07-25T00:00:00.000Z</StatusDate><Source id="801350" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3467">Metastatic renal cancer</Indication><StatusDate>2007-07-25T00:00:00.000Z</StatusDate><Source id="801350" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2009-08-03T00:00:00.000Z</StatusDate><Source id="1220037" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate>2011-01-09T00:00:00.000Z</StatusDate><Source id="1178458" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2007-09-13T00:00:00.000Z</StatusDate><Source id="824548" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2009-08-03T00:00:00.000Z</StatusDate><Source id="1220037" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1767">Hepatocellular carcinoma</Indication><StatusDate>2009-08-03T00:00:00.000Z</StatusDate><Source id="1220037" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2007-09-13T00:00:00.000Z</StatusDate><Source id="824548" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2011-02-28T00:00:00.000Z</StatusDate><Source id="1342685" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23215">Takeda Bio Development Center Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2011-01-24T00:00:00.000Z</StatusDate><Source id="1162980" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23215">Takeda Bio Development Center Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2011-01-24T00:00:00.000Z</StatusDate><Source id="1162980" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23215">Takeda Bio Development Center Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2011-01-24T00:00:00.000Z</StatusDate><Source id="1162980" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2014-04-01T00:00:00.000Z</StatusDate><Source id="1745504" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2014-04-01T00:00:00.000Z</StatusDate><Source id="1745504" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2014-04-01T00:00:00.000Z</StatusDate><Source id="1745504" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-03-23T00:00:00.000Z</StatusDate><Source id="528612" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2005-11-14T00:00:00.000Z</StatusDate><Source id="634908" type="CONFERENCE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2006-06-01T00:00:00.000Z</StatusDate><Source id="677050" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2008-02-04T00:00:00.000Z</StatusDate><Source id="873461" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23215">Takeda Bio Development Center Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2008-04-01T00:00:00.000Z</StatusDate><Source id="892192" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2007-09-06T00:00:00.000Z</StatusDate><Source id="809143" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2007-09-06T00:00:00.000Z</StatusDate><Source id="809143" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2007-09-06T00:00:00.000Z</StatusDate><Source id="809143" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2007-09-06T00:00:00.000Z</StatusDate><Source id="809143" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2007-09-06T00:00:00.000Z</StatusDate><Source id="809143" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2007-09-06T00:00:00.000Z</StatusDate><Source id="809143" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23215">Takeda Bio Development Center Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-08-24T00:00:00.000Z</StatusDate><Source id="1038528" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2009-03-12T00:00:00.000Z</StatusDate><Source id="961451" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2009-03-12T00:00:00.000Z</StatusDate><Source id="961451" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2009-03-12T00:00:00.000Z</StatusDate><Source id="961451" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2009-03-31T00:00:00.000Z</StatusDate><Source id="1220430" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2009-03-31T00:00:00.000Z</StatusDate><Source id="1220430" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="49">Breast tumor</Indication><StatusDate>2009-03-31T00:00:00.000Z</StatusDate><Source id="1220430" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2011-01-13T00:00:00.000Z</StatusDate><Source id="1220435" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2011-01-13T00:00:00.000Z</StatusDate><Source id="1220435" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3083">Peritoneal tumor</Indication><StatusDate>2011-01-13T00:00:00.000Z</StatusDate><Source id="1220435" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="799">Ovary tumor</Indication><StatusDate>2011-01-13T00:00:00.000Z</StatusDate><Source id="1220435" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2011-01-13T00:00:00.000Z</StatusDate><Source id="1220435" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="BE">Belgium</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2011-01-13T00:00:00.000Z</StatusDate><Source id="1220435" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="14109">Amgen Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2243">Fallopian tube cancer</Indication><StatusDate>2011-01-13T00:00:00.000Z</StatusDate><Source id="1220435" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20300">Takeda Pharmaceutical Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="799">Ovary tumor</Indication><AwardedIndication>Treatment of ovarian cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-11-13T00:00:00.000Z</MileStoneDate><Source id="1515390" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="20300">Takeda Pharmaceutical Co Ltd</OwnerCompany><Country id="EU">EU</Country><Indication id="799">Ovary tumor</Indication><AwardedIndication>Treatment of ovarian cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate>2013-10-09T00:00:00.000Z</MileStoneDate><Source id="1488978" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="14109">Amgen Inc</OwnerCompany><Country id="US">US</Country><Indication id="799">Ovary tumor</Indication><AwardedIndication>Treatment of ovarian cancer</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2013-08-30T00:00:00.000Z</MileStoneDate><Source id="1476453" type="CORPORATE"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01826"><Name>Tek tyrosine kinase receptor</Name><SwissprotNumbers><Swissprot>Q02763</Swissprot><Swissprot>Q02858</Swissprot><Swissprot>Q06807</Swissprot></SwissprotNumbers></Target><Target id="PTGT-03653"><Name>Angiopoietin ligand-1</Name><SwissprotNumbers><Swissprot>O08538</Swissprot><Swissprot>O18920</Swissprot><Swissprot>O35460</Swissprot><Swissprot>Q15389</Swissprot><Swissprot>Q60FC1</Swissprot></SwissprotNumbers></Target><Target id="PTGT-03654"><Name>Angiopoietin ligand-2</Name><SwissprotNumbers><Swissprot>O15123</Swissprot><Swissprot>O35462</Swissprot><Swissprot>O35608</Swissprot><Swissprot>O77802</Swissprot><Swissprot>Q9BDY7</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2001290" linkType="reference" linkID="2001290"&gt;2001290&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="14109">Amgen Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="111534" title="Takeda to develop Amgen's biologic compounds in Japan for oncology, pain and inflammation"/><Deal id="120669" title="Amgen to apply Dyax's phage display library"/></Deals><PatentFamilies><PatentFamily id="1959053" number="WO-2007124090" title="Lyophilized therapeutic peptibody formulations"/><PatentFamily id="2063776" number="WO-2004092215" title="Methods of treatment using specific binding agents of human angiopoietin-2"/><PatentFamily id="2066827" number="WO-2009026122" title="Formulations of antibodies and Fc-fusion molecules using polycations"/><PatentFamily id="2440492" number="WO-2013003606" title="Predictive biomarker of survival in the treatment of renal cell carcinoma"/><PatentFamily id="298998" number="WO-2009158432" title="Ang-2 inhibition to treat multiple sclerosis"/><PatentFamily id="3434356" number="WO-2016176427" title="Treatment of ovarian cancer in patients with ascites using a specific binding agent of human angiopoietin-2 in combination with a taxane"/><PatentFamily id="3489683" number="WO-2016209972" title="Biomarker of survival in the treatment of renal cell carcinoma with a VEGFR inhibitor and an Ang2 inhibitor"/><PatentFamily id="4221736" number="WO-2018187355" title="MET kinase inhibitors and uses therefor"/><PatentFamily id="432906" number="WO-2009015345" title="Pharmaceutical compositions comprising Fc fusion proteins"/><PatentFamily id="4388699" number="WO-2019028012" title="Methods of using pembrolizumab and trebananib"/><PatentFamily id="592692" number="WO-2011038139" title="Treatment of ovarian cancer using a specific binding agent of human angiopoietin-2 in combination with a taxane"/><PatentFamily id="843837" number="WO-03057134" title="Specific binding agents of human angiopoietin-2"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="New York State Department Of Health" id="1032011"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Amgen Inc" id="14109"/><CountAsOwner>10</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>10</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>